Podcasts about mrd

Wir sehen erneut überwiegend robuste Ergebnisse, mit den Aktien von Taiwan Semiconductor, GE Aerospace und Pepsi unter den Gewinnern. United Airlines und US Bancorp tendieren nach den Zahlen schwächer. Neben dem soliden Start in die Berichtssaison, sehen wir eine Beschleunigung der Wirtschaft. Die Einzelhandelsumsätze für den Juni lagen deutlich über den Zielen, bei gleichzeitig sinkenden Erstanträgen für Arbeitslosenhilfe. Eine Zinssenkung wird damit zunehmend unwahrscheinlich. Heute Abend werden die Ergebnisse von Netflix im Fokus stehen. Analysten rechnen mit einem Ertrag pro Aktie von $7.08, mit einem Umsatz von $11,07 Mrd, was im Vorjahresvergleich einem Ertragswachstum von 45% entspricht. Abonniere den Podcast, um keine Folge zu verpassen! ____ Folge uns, um auf dem Laufenden zu bleiben: • X: http://fal.cn/SQtwitter • LinkedIn: http://fal.cn/SQlinkedin • Instagram: http://fal.cn/SQInstagram

Wir sehen erneut überwiegend robuste Ergebnisse, mit den Aktien von Taiwan Semiconductor, GE Aerospace und Pepsi unter den Gewinnern. United Airlines und US Bancorp tendieren nach den Zahlen schwächer. Neben dem soliden Start in die Berichtssaison, sehen wir eine Beschleunigung der Wirtschaft. Die Einzelhandelsumsätze für den Juni lagen deutlich über den Zielen, bei gleichzeitig sinkenden Erstanträgen für Arbeitslosenhilfe. Eine Zinssenkung wird damit zunehmend unwahrscheinlich. Heute Abend werden die Ergebnisse von Netflix im Fokus stehen. Analysten rechnen mit einem Ertrag pro Aktie von $7.08, mit einem Umsatz von $11,07 Mrd, was im Vorjahresvergleich einem Ertragswachstum von 45% entspricht. Ein Podcast - featured by Handelsblatt. +++Erhalte einen exklusiven 15% Rabatt auf Saily eSIM Datentarife! Lade die Saily-App herunter und benutze den Code wallstreet beim Bezahlen: https://saily.com/wallstreet +++ +++EXKLUSIVER NordVPN Deal ➼ https://nordvpn.com/Wallstreet Jetzt risikofrei testen mit einer 30-Tage-Geld-zurück-Garantie!+++ +++ Alle Rabattcodes und Infos zu unseren Werbepartnern findet ihr hier: https://linktr.ee/wallstreet_podcast +++ Der Podcast wird vermarktet durch die Ad Alliance. Die allgemeinen Datenschutzrichtlinien der Ad Alliance finden Sie unter https://datenschutz.ad-alliance.de/podcast.html Die Ad Alliance verarbeitet im Zusammenhang mit dem Angebot die Podcasts-Daten. Wenn Sie der automatischen Übermittlung der Daten widersprechen wollen, klicken Sie hier: https://datenschutz.ad-alliance.de/podcast.html

Dr. Ben Derman of the University of Chicago Medicine joins the show to unpack major updates in multiple myeloma presented at ASCO and EHA 2025. He discusses the growing role of quadruple therapy across all patient populations and its implications for the future of autologous stem cell transplant, including insights from the MIDAS trial on MRD-guided transplant decisions. Additional highlights include MRD-negativity as a potential off-ramp for maintenance therapy, evolving data from frontline triplet vs. quadruplet studies, real-world referral trends, CARTITUDE-4 subgroup outcomes, and the expanding utility of bispecifics and trispecific antibodies, particularly for extramedullary disease. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Der Dax und die US-Börsen notieren nahe oder auf Rekordständen. Doch der bei deutschen Sparern so beliebte MSCI World hinkt hinterher und liegt seit Jahresbeginn noch rund zwei Prozent im Minus. Die beiden Wirtschaftsjournalisten Dietmar Deffner und Holger Zschäpitz diskutieren einen neuen, aktiv gemanagten Welt-ETF, der mit nur 25 Werten den MSCI deutlich geschlagen hat und im laufenden Jahr fast zwölf Prozent im Plus liegt. Weitere Themen: - Comeback der Rohstoffe – diese Aktie ist eine Wette auf die vier Zukunftsmetalle Eisenerz, Kupfer, Aluminium, Lithium - Ausgaben für Bürgergeld steigen weiter – warum die Grundsicherung nur schwer zu reformieren ist - Kosten für staatliche Rente steigen um 50 Mrd. Euro bis 2030 – warum die Regierung schnell gegensteuern muss - Trumps neuer Zollhammer – was 30 Prozent Importzölle auf europäische Güter für Deutschland bedeuten würde DEFFNER & ZSCHÄPITZ sind wie das wahre Leben. Wie Optimist und Pessimist. Im wöchentlichen WELT-Podcast diskutieren und streiten die Journalisten Dietmar Deffner und Holger Zschäpitz über die wichtigen Wirtschaftsthemen des Alltags. Schreiben Sie uns an: wirtschaftspodcast@welt.de Produktion: Dieter Webel Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutzerklärung: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Cognition schnappt sich Windsurf nach Googles spektakulärem „Talent-Heist“, während Elon Musk xAI per SpaceX-Milliarden auf eine 200-Mrd.-$-Bewertung pumpt. Mark Zuckerberg kontert mit gigantischen Titan-Clustern (Prometheus & Hyperion) und verspricht dreistellige Milliarden-Investitionen in KI-Rechenpower. Chip-Newcomer Groq peilt 6 Mrd.$ an, Nvidia darf mit den H20-Beschleunigern wieder nach China liefern, und Grok 4 glänzt in Benchmarks – muss sich aber für „MechaHitler“-Entgleisungen entschuldigen. Unterstütze unseren Podcast und entdecke die Angebote unserer Werbepartner auf ⁠⁠⁠⁠⁠doppelgaenger.io/werbung⁠⁠⁠⁠⁠. Vielen Dank!  Philipp Glöckler und Philipp Klöckner sprechen heute über: (00:00:00) Windsurf-Deal (00:08:30) xAI-Runde: 200 Mrd.$ Bewertung, 2 Mrd.$ von SpaceX (00:21:30) Meta-Titan-Cluster: Prometheus / Hyperion > 1 GW (00:26:50) Groq-Raise: LPU-Chips zu 6 Mrd.$ (00:25:45) USA lockern: Nvidia H20 & AMD-MI300 für China (00:34:10) Grok 4: Benchmark-Sieg, Bias & Überwachungs-Tool Shownotes Cognition übernimmt Windsurf – techcrunch.com Elon Musks xAI strebt $200 Mrd. Bewertung an – on.ft.com Exklusiv: SpaceX investiert 2 Milliarden Dollar in Elon Musks xAI – wsj.com Peter Gostev zu Grok 4 sind mehrere unabhängige Benchmarks aufgetaucht. – linkedin.com Zuckerberg: Meta plant Gigawatt-Datenzentren – bloomberg.com Superintelligenz: Elite-Team und Milliardeninvestitionen in Rechenleistung – threads.com Elon Musk überwacht Mitarbeiter seiner KI-Firma – thedailybeast.com Nvidia-Herausforderer Groq: $6 Milliarden Bewertung – theinformation.com xAI und Grok entschuldigen sich für „schreckliches Verhalten“ – techcrunch.com Nvidia, AMD verkaufen wieder KI-Chips an China – bloomberg.com Grok: Interaktive KI-Begleiter auf iOS mit 3D-Avataren – testingcatalog.com Trump behielt Goldpokal, FIFA gab Replikat an Sieger – thedailybeast.com

In this episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Sagar Lonial, MD, FACP, discuss key topics with CELMoD therapy for multiple myeloma, including: Mechanistic differences between CELMoDs and IMiDsEmerging data with CELMoDs and their potential therapeutic roles across the disease continuum of multiple myelomaThe clinical implications of MRD negativity as a surrogate marker of long-term outcomes in clinical trials in multiple myelomaPresenters:Jesus Berdeja, MDDirector of Myeloma ResearchGreco-Hainsworth Centers for ResearchTennessee OncologyNashville, TennesseeAmrita Krishnan, MD, FACPDirector, Judy and Bernard Briskin Center for MyelomaExecutive Director of HematologyCity of Hope Orange CountyProfessor of Hematology/HCTCity of Hope Cancer CenterIrvine, CaliforniaSagar Lonial, MD, FACPChair and ProfessorDepartment of Hematology and Medical OncologyAnne and Bernard Gray Family Chair in CancerChief Medical OfficerWinship Cancer InstituteEmory UniversityAtlanta, GeorgiaContent based on an online CME program supported by an independent educational grant from Bristol Myers Squibb.Link to full program: https://bit.ly/3IwbslQ

NVIDIA bekommt von der Trump-Administration grünes Licht und darf den H20 Chip in China verkaufen. Die Tech-Euphorie wird durch diese Meldung gespeist, zumal dadurch auch eine voranschreitende Stabilisierung im Handelskonflikt beider Nationen signalisiert wird. Laut Bloomberg soll Trump heute außerdem $70 Milliarden an Investitionen in die KI-Stromversorgung melden. Google plant über die nächsten zwei Jahre $25 Mrd. in die Stromversorgung für Data Center und KI-Infrastruktur zu investieren. Ansonsten setzt die Wall Street darauf, dass die für den 1. August angedrohte Ausweitung der Zölle gegenüber den wichtigsten Handelspartnern in dieser Form nicht kommen werden. Der TACO-Trade bleibt somit in Takt. Die vor dem Opening gemeldeten Ergebnisse aus dem Bankensektor halten die optimistische Stimmung ein und fallen überwiegend solide aus. BlackRock, JP Morgan, die Citigroup und Wells Fargo konnten die Ertragsziele jeweils schlagen. Da Wells Fargo die erwarteten Netto-Zinseinnahmen senkt, steht der Wert aber eicht unter Druck. Die Aktien von Trade Desk werden ab Freitag im S&P 500 aufgenommen, mit vorbörslich starken Kursgewinnen. Wir haben außerdem viele positive Analystenstimmen zum Tech-Sektor. Die Ziele für Google, Meta, Microsoft und Netflix werden angehoben. Was Inflation betrifft, lagen die Juni-Verbraucherpreise lagen so ziemlich im Rahmen der Ziele. Abonniere den Podcast, um keine Folge zu verpassen! ____ Folge uns, um auf dem Laufenden zu bleiben: • X: http://fal.cn/SQtwitter • LinkedIn: http://fal.cn/SQlinkedin • Instagram: http://fal.cn/SQInstagram

NVIDIA bekommt von der Trump-Administration grünes Licht und darf den H20 Chip in China verkaufen. Die Tech-Euphorie wird durch diese Meldung gespeist, zumal dadurch auch eine voranschreitende Stabilisierung im Handelskonflikt beider Nationen signalisiert wird. Laut Bloomberg soll Trump heute außerdem $70 Milliarden an Investitionen in die KI-Stromversorgung melden. Google plant über die nächsten zwei Jahre $25 Mrd. in die Stromversorgung für Data Center und KI-Infrastruktur zu investieren. Ansonsten setzt die Wall Street darauf, dass die für den 1. August angedrohte Ausweitung der Zölle gegenüber den wichtigsten Handelspartnern in dieser Form nicht kommen werden. Der TACO-Trade bleibt somit in Takt. Die vor dem Opening gemeldeten Ergebnisse aus dem Bankensektor halten die optimistische Stimmung ein und fallen überwiegend solide aus. BlackRock, JP Morgan, die Citigroup und Wells Fargo konnten die Ertragsziele jeweils schlagen. Da Wells Fargo die erwarteten Netto-Zinseinnahmen senkt, steht der Wert aber eicht unter Druck. Die Aktien von Trade Desk werden ab Freitag im S&P 500 aufgenommen, mit vorbörslich starken Kursgewinnen. Wir haben außerdem viele positive Analystenstimmen zum Tech-Sektor. Die Ziele für Google, Meta, Microsoft und Netflix werden angehoben. Was Inflation betrifft, lagen die Juni-Verbraucherpreise lagen so ziemlich im Rahmen der Ziele. Ein Podcast - featured by Handelsblatt. +++Erhalte einen exklusiven 15% Rabatt auf Saily eSIM Datentarife! Lade die Saily-App herunter und benutze den Code wallstreet beim Bezahlen: https://saily.com/wallstreet +++ +++EXKLUSIVER NordVPN Deal ➼ https://nordvpn.com/Wallstreet Jetzt risikofrei testen mit einer 30-Tage-Geld-zurück-Garantie!+++ +++ Alle Rabattcodes und Infos zu unseren Werbepartnern findet ihr hier: https://linktr.ee/wallstreet_podcast +++ Der Podcast wird vermarktet durch die Ad Alliance. Die allgemeinen Datenschutzrichtlinien der Ad Alliance finden Sie unter https://datenschutz.ad-alliance.de/podcast.html Die Ad Alliance verarbeitet im Zusammenhang mit dem Angebot die Podcasts-Daten. Wenn Sie der automatischen Übermittlung der Daten widersprechen wollen, klicken Sie hier: https://datenschutz.ad-alliance.de/podcast.html

Herzlich willkommen zur 151. Folge des Equistor-Podcasts

On this week's show current Alabama Marine Resources Director Scott Bannon joins Sean and Mike to talk about snapper numbers and changes to other fish species creel and size limits. He also announces his retirement from MRD and his new job. 

Nvidia durchbricht erstmals die Marke von 4 Billionen US-$ Marktkapitalisierung, während der Bitcoin-Kurs über 118 000 € klettert. Zugleich starten neue „Browser Wars“: OpenAI arbeitet an einem eigenen KI-Browser, Perplexity stellt Comet vor. Mistral AI verhandelt über eine Finanzierungsrunde, Amazon lotet ein weiteres Investment in Anthropic aus, und Figma legt beeindruckende IPO-Zahlen vor. Bei X häufen sich Abgänge – Linda Yaccarino tritt als CEO zurück, Grok-4 überzeugt technisch, fällt jedoch mit ideologisch gefärbten Antworten auf. Anduril erhält dank neuer Grenzschutz-Vorgaben quasi exklusiv den Auftrag für autonome Überwachungstürme, während Binance laut Bloomberg Trumps Stablecoin-Projekt technisch unterstützt. DeepMind-Ableger Isomorphic Labs startet erste klinische Studien mit KI-designten Wirkstoffen. Unterstütze unseren Podcast und entdecke die Angebote unserer Werbepartner auf ⁠⁠⁠⁠⁠doppelgaenger.io/werbung⁠⁠⁠⁠⁠. Vielen Dank!  Philipp Glöckler und Philipp Klöckner sprechen heute über: (00:00:00) Mega-Caps: Nvidia ≥ 4 T $, Bitcoin 118 k € (00:01:45 ) KI-Browser | OpenAI vs. Perplexity (00:10:30) Mistral-AI >1 Mrd.$-Runde | Amazon ↗ Anthropic (00:13:10) Figma-IPO (00:22:00) Linda Yaccarino geht, DOGE-Team löst sich auf (00:25:30) Grok 4: Benchmark-Spitze & Musk-Bias (00:46:40) Anduril sichert sich autonome Grenztürme (00:48:30) Binance-Code in Trumps Stablecoin-Plänen (00:49:50) Isomorphic Labs: AlphaFold-Wirkstoffe im Menschen­test Shownotes Grok Makes Bizarre Post About Elon Musk and Jeffrey Epstein – yahoo.com Elon Musks KI-Chatbot Grok startet antisemitische Tirade – washingtonpost.com Grok nennt sich jetzt MechaHitler. – x.com Musk enthüllt Grok 4 KI-Chatbot nach Antisemitismus-Kontroverse – bloomberg.com Das Memo - Sonderausgabe - xAI Grok 4 - Jul/2025 – lifearchitect.substack.com OpenAI plant Webbrowser als Herausforderung für Google Chrome – Reuters Altman Interview mit Brille – youtube.com Perplexity startet Comet, einen KI-gestützten Webbrowser – techcrunch.com Mistral in Gesprächen zur Kapitalbeschaffung mit Abu Dhabi Fund MGX – bloomberg.com Amazon erwägt weitere Investition in Anthropic – ft.com Figma plant Börsengang – cnbc.com from:elonmusk (Israel OR Palestine OR Hamas OR Gaza)– x.com Linda Yaccarino nicht mehr CEO von Elon Musks X – edition.cnn.com Core DOGE staffers follow Musk out the door – politico.com Trumps großes Geschenk an Anduril – theintercept Binance unterstützte Trump-Krypto-Firma vor CZs Begnadigungsantrag – bloomberg.com Isomorphic Labs bereitet erste klinische Studien mit AlphaFold-entwickelten Medikamenten vor – the-decoder.com Frank Thelen verkauft Scanbot SDK an Apryse – handelsblatt.com

In this episode, Jonathan Sackier welcomes Claudio Cerchione, haematologist and researcher at the Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. From his early interest in plasma cell disorders, Cerchione shares key insights into the evolution of multiple myeloma (MM) research, the rising role of minimal residual disease (MRD), and promising developments in monoclonal antibodies and CAR-T therapy. He also reflects on standout moments from recent European Hematology Association (EHA) Congress and American Society of Clinical Oncology (ASCO) Annual Meeting, and shares his hopes for the future of haematology.   Timestamps: 2:14: Memorable career experiences for Claudio   4:20 Biggest breakthrough in MM  5:10 Interest in plasma cell disorders  6:30 A surprising fact about multiple myeloma  7:40 Claudio's top choice for a dinner party guest  10:30 The importance of MRD in haematology  13:00 Monoclonal antibodies and CAR-T therapies  19:00 Current challenges  22:22 Claudio's key EHA and ASCO takeaways  28:30 Claudio's three magic wishes  

Catherine Lai, MD, MPH, University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, PA Recorded on June 27, 2025 Catherine Lai, MD, MPH Associate Professor Physician Leader, Leukemia Clinical Research Unit University of Pennsylvania Perelman Center for Advanced Medicine Philadelphia, PA In this episode, Dr. Catherine Lai, from the University of Pennsylvania's Perelman Center for Advanced Medicine, joins us to discuss the current landscape of adult acute lymphoblastic leukemia (ALL) treatment. She highlights recent advances in frontline and relapsed therapies, the critical role of measurable residual disease (MRD), and the use of immunotherapy and targeted treatments. Dr. Lai further explores transplant considerations, management of side effects, and tailored approaches for B-cell and T-cell ALL. She also emphasizes patient-centered care, including strategies for end-of-life discussions and shared decision-making. Tune in today for expert insights and practical takeaways on the evolving future of ALL care!

OpenAI distanziert sich von Robinhoods „OpenAI-Token“, steckt mehr als 4 Mrd. $ in Aktienvergütung bei nur 3,9 Mrd. Umsatz und zieht nach mutmaßlichem Spionageversuch von DeepSeek die Security-Schrauben an, während Huawei sein Pangu-Lab gegen Plagiatsvorwürfe verteidigt; Stripe zeigt, dass KI-Start-ups doppelt so schnell internationalisieren wie klassisches SaaS, Forscher schmuggeln versteckte „Bitte positiv bewerten“-Prompts in Papers, eine Allianz kleiner EU-Verleger reicht Kartellbeschwerde gegen Googles AI-Overviews ein, Sequoia-Partner Shaun Maguire entfacht mit islamfeindlichen Posts einen Aufschrei von Gründer-CEOs, Elon Musk gründet trotz Tesla-Absatzrückgang und Kursverlusten die „America Party“ und Jack Dorsey präsentiert BitChat als dezentralen Bluetooth-Messenger ohne Internet. Unterstütze unseren Podcast und entdecke die Angebote unserer Werbepartner auf ⁠⁠⁠⁠⁠doppelgaenger.io/werbung⁠⁠⁠⁠⁠. Vielen Dank!  Philipp Glöckler und Philipp Klöckner sprechen heute über: (00:00:00) Intro (00:03:40) OpenAI-Token bei Robinhood – was steckt wirklich dahinter?   (00:08:30) Aktienvergütung (SBC) & Verwässerung bei OpenAI erklärt   (00:14:50) OpenAI schärft Security – DeepSeek, Spionage & Huawei-Vorwürfe   (00:18:50) Stripe-Daten: AI-Start-ups wachsen doppelt so schnell   (00:27:10) EU-Beschwerde: Google AI Overviews unter Kartell-Druck   (00:31:20) Sequoia-Partner Shaun Maguire in Islamophobie-Kritik   (00:35:00) Elon Musk gründet die „America Party“ – Tesla reagiert   (00:46:00) BitChat: Jack Dorseys Bluetooth-Messenger ohne Internet   Shownotes OpenAI verurteilt Robinhoods 'OpenAI Tokens' – techcrunch.com OpenAIs Aktienvergütung spiegelt hohe Kosten des Talentkampfs wider – theinformation.com OpenAI verstärkt Sicherheit nach Spionagebedrohungen – ft.com Huawei's KI-Labor wehrt sich gegen Vorwürfe – bloomberg.com Top 100 KI-Unternehmen übertreffen SaaS global – x.com Researchers hide AI prompts in papers – asia.nikkei.com Google sieht sich EU-Wettbewerbsbeschwerde wegen KI-Übersichten gegenüber – techcrunch.com Sequoia-Partner Maguire Beiträge über Mamdani lösen Gründer-Petition aus – bloomberg.com Trumps Steueränderungen für Reiche – cnbc.com Elon Musk gründet »America Party« in den USA – spiegel.de Tesla-Aktien fallen nach Ankündigung neuer US-Partei – ft.com Jack Dorsey startet WhatsApp-Rivalen auf Bluetooth-Basis – cnbc.com

Die Themen im heutigen Versicherungsfunk Update sind: Mehr Makler, weniger Vertreter: Unabhängige Beratung legt weiter zu Trotz eines Rückgangs der Gesamtzahl registrierter Versicherungsvermittler auf 179.923 (–1,7 %) wächst die Zahl unabhängiger Makler weiter leicht: +0,5 % auf 46.771. Besonders stark betroffen ist der Ausschließlichkeitsvertrieb (–3,3 %). Auch § 34f- und § 34i-Vermittler legten leicht zu. Für AfW-Vorstand Norman Wirth ein klares Signal: „Das Maklermodell ist zukunftsfähig – trotz wachsender Regulierung.“ wefox sichert sich 151 Mio. EUR zur Expansion und Rückkehr zur Profitabilität Das Insurtech wefox hat sich frisches Kapital in Höhe von 151 Mio. EUR gesichert – davon 76 Mio. über eine Kapitalerhöhung, weitere 75 Mio. durch Refinanzierung bestehender Kredite. Die Mittel sollen zur Expansion in Österreich, den Niederlanden und der Schweiz sowie zum Ausbau des MGA- und Maklergeschäfts dienen. Das Unternehmen strebt im Geschäftsjahr 2025 die Rückkehr zur Profitabilität an. Im Zuge der Finanzierungsrunde wurde auch der Verwaltungsrat neu besetzt. Mütterrente III: Umsetzung frühestens 2028 – mit Rückwirkung Die Deutsche Rentenversicherung warnt vor einer Umsetzung der Mütterrente III ab 2027: Der Programmieraufwand sei so hoch, dass eine technische Umsetzung erst ab 2028 realistisch sei. Der Koalitionsausschuss erkennt die Komplexität an und hält eine rückwirkende Auszahlung für möglich. Betroffen wären über 10 Mio. Renten. Versorgungswerke: Rund 2.200 EUR Altersrente im Schnitt Rund 938.000 Mitglieder zahlten 2023 in ein berufsständisches Versorgungswerk ein, etwa 340.000 erhielten eine Altersrente. Diese betrug im Durchschnitt rund 2.200 EUR monatlich. Das gesamte Beitragsvolumen belief sich laut Bundesregierung auf 12,4 Mrd. EUR. Dorothee Andrzejewski neu in der Geschäftsführung von ATRALOsecur Die SCHUNCK GROUP verstärkt die Führung ihres Assekuradeurs ATRALOsecur GmbH: Dorothee Andrzejewski ist seit 1. Juni neue Geschäftsführerin neben Daniel Ahrend und Peter Kollatz. Andrzejewski bringt umfangreiche Erfahrung aus ihrer Zeit bei AIG und der SCHUNCK GROUP mit. Künftig verantwortet sie unter anderem Strategie, Budget und Weiterentwicklung im Transportversicherungsbereich. Photovoltaik-Boom hält an: 4,2 Mio. Anlagen in Deutschland Die Zahl der Photovoltaikanlagen in Deutschland ist im März auf über 4,2 Mio. gestiegen – ein Plus von 23,7 % im Vergleich zum Vorjahr. Auch die installierte Leistung legte deutlich zu und erreichte rund 98.300 MW (+21,9 %), so das Statistische Bundesamt. Balkonkraftwerke sind in der Statistik nicht enthalten.

Geld oder kein Geld – das ist hier die Frage: Vorerst gibt es also keine Senkung der Stromsteuer für alle Firmen und Privatpersonen gleichermaßen - das hatten CDU, CSU und SPD aber im Koalitionsvertrag vereinbart. Antwort also: kein Geld. Entlastet werden Verbraucher:innen und Unternehmen mit ca. 10 Mrd. Euro zunächst u.a. über den Gaspreis – genügend, sagt die Bundesregierung; von "Wortbruch" sprechen gar Wirtschaftsverbände. Und jetzt? Der Chef des Bundeskanzleramtes, Thorsten Frei (CDU), und Brandenburgs Finanzminister, Robert Crumbach (BSW), diskutieren bei Michaela Kolster.

Mon, 07 Jul 2025 03:45:00 +0000 https://jungeanleger.podigee.io/2392-borsepeople-im-podcast-s19-19-kurt-kerschbaum ea126da64316f3c93e16af726af8f0bd Kurt Kerschbaum ist Direktor der OeKB CSD, die unlängst ihren 10. Geburtstag feierte. Wir sprechen über lange Jahre bei der UniCredit, wo Kurt nach und nach in Führungspositionen aufstieg und dann - kurz nach der Gründung der OeKB CSD - den Wechsel eben dorthin. Und es wird tief eingetaucht, es geht um die Integrität der Urkunden, knapp 20.000 verwahrte Wertpapierkategorien (ISINs), 1.644.470 abgewickelte Transaktionen 2024, rund 850 Mrd. Euro Verwahrwert Anleihen, Aktien & Fonds und die Novelle des Depotgesetzes, die die rein elektronische Begebung von Wertpapieren ermöglichte, was zu Kurts Steckenpferd wurde. Auch da haben wir viele Zahlen. Wir sprechen aber auch über Dividenden, die Zusammenarbeit mit der CCPA, Shortpositionen, FMA und OeNB, Settlementfails sowie einen typischen Tagesablauf. Und Schach. https://www.oekb-csd.at Erklärvideo zur CSD: https://www.youtube.com/watch?v=U10TkkHgwRE About: Die Serie Börsepeople des Podcasters Christian Drastil, der im Q4/24 in Frankfurt als "Finfluencer & Finanznetworker #1 Austria" ausgezeichnet wurde, findet im Rahmen von http://www.audio-cd.at und dem Podcast "Audio-CD.at Indie Podcasts" statt. Es handelt sich dabei um typische Personality- und Werdegang-Gespräche. Die Season 19 umfasst unter dem Motto „25 Börsepeople“ 25 Talks. Presenter der Season 19 ist die Volksbank https://www.volksbank.at. Welcher der meistgehörte Börsepeople Podcast ist, sieht man unter http://www.audio-cd.at/people. Der Zwischenstand des laufenden Rankings ist tagesaktuell um 12 Uhr aktualisiert. Bewertungen bei Apple (oder auch Spotify) machen mir Freude: http://www.audio-cd.at/spotify , http://www.audio-cd.at/apple . 2392 full no Christian Drastil Comm. 2101

Marketing im Kopf - ein Podcast von Luis BinderIn dieser Folge wird über verschiedene Unternehmen gesprochen, da Markennamen genannt werden, handelt es sich um UNBEZAHLTE WERBUNG!In dieser Folge: In der heutigen Podcastfolge von Marketing im Kopf geht's um die letzten zwei Grundbestandteile der Werbepsychologie und darum, wie deine Werbebotschaft nicht nur verstanden, sondern auch erinnert und akzeptiert wird. Du erfährst, warum Wiederholung und passende Reize so wichtig sind, wie du mit Farben und Bildern Emotionen auslösen kannst und welche sechs Trigger besonders gut funktionieren, von FOMO bis Sparsamkeit.____________________________________________Marketing-News der Woche:Werbewirtschaft trotzt der KriseTrotz wirtschaftlicher Flaute legte die deutsche Werbewirtschaft 2024 um 2,2 % auf rund 49,9 Mrd. Euro zu. Besonders digitale Kanäle wie Online- und Außenwerbung trieben das Wachstum: Digitale Außenwerbung stieg um über 35 %. Auch Bewegtbildformate und Radio entwickelten sich stabil, während Print erneut rückläufig war. Der ZAW betont die anhaltende Relevanz von Werbung als konjunkturunabhängiger Wirtschaftsfaktor und ruft zugleich zur besseren politischen Unterstützung auf.OpenAI startet erste ChatGPT-KampagneErstmals bewirbt OpenAI sein Produkt ChatGPT aktiv über klassische Werbemaßnahmen. Die neue Kampagne soll die Markenbekanntheit steigern und die Nutzerbasis erweitern. Konkrete Inhalte oder Platzierungen werden zwar nicht offengelegt, doch der Schritt zeigt, dass selbst KI-Pioniere zunehmend auf traditionelle Marketingstrategien setzen und dabei auf ein klares Markenprofil achten.Zoom-Chef lässt KI-Avatar sprechenZoom-CEO Eric Yuan überließ seinen Auftritt zur Quartalskonferenz einem KI-generierten Avatar, produziert mit der firmeneigenen Videoplattform. Ziel war es, die eigenen Tools zu demonstrieren und die Effizienz asynchroner Kommunikation hervorzuheben. Auch andere Tech-Firmen experimentieren mit KI-Avataren auf Führungsebene, um Markenbotschaften innovativ zu inszenieren.⁠Nur jede fünfte Marke ist krisenfestLaut Markenresilienz-Index 2024 sind nur 19 % der untersuchten Marken in Deutschland sowohl preis- als auch volumenstabil. Knapp die Hälfte gelten als fragil, weil ihnen entweder klare Positionierung oder Anpassungsfähigkeit fehlt. Tempo, Samsung, Nivea, Coca-Cola und Miele führen das Ranking an. Sie vereinen Markenstärke mit konsequenter Kommunikation und Innovationskraft. Auffällig: Vor allem Traditionsmarken zeigen Widerstandsfähigkeit.____________________________________________Vernetz dich gerne auf LinkedIn: ⁠https://www.linkedin.com/in/luisbinder/⁠ Instagram: https://www.instagram.com/marketingimkopf/Du hast Fragen, Anregungen oder Ideen? Melde dich unter: marketingimkopf@gmail.com Die Website zum Podcast findest du hier. [⁠⁠⁠https://bit.ly/2WN7tH5⁠⁠⁠]

147.000 neue Jobs in den USA – der Arbeitsmarkt läuft heiß, Zinssenkungen aber auf Eis. Der DAX steigt um 0,6 % auf 23.934 Punkte. SAP ist jetzt Europas wertvollster Konzern. BayWa rutscht mit 1,6 Mrd. Verlust tief in die roten Zahlen, Uniper streicht Jobs. Redcare Pharmacy wächst stark, HHLA kürzt die Dividende. Im Podcast: Reploid, Naoo, Laiqon und ein heißer Automatendeal! Mit dabei: Stefan Mayerhofer von Laiqon – und Andreas Groß für Börsenradio.de.

Die Themen im heutigen Versicherungsfunk Update sind: SDK und Stuttgarter besiegeln Gleichordnungskonzern Die SDK Gruppe und die Stuttgarter Versicherungsgruppe haben ihren Zusammenschluss zum 1. Juli vollzogen. Beide Versicherer agieren künftig als Gleichordnungskonzern mit einer wechselseitigen Personalunion in den Vorstandsgremien. Mit rund 1.600 Mitarbeitern, über 1,85 Mrd. EUR Beitragseinnahmen und mehr als 1,8 Mio. Verträgen entsteht eine neue Versicherungsgruppe mit Fokus auf Kranken-, Lebens- und Unfallversicherung. Eine neue gesellschaftsrechtliche Struktur ist bis Ende 2026 geplant. Signal Iduna mit neuem Vorstandsvorsitzenden: Torsten Uhlig folgt auf Ulrich Leitermann Führungswechsel bei Signal Iduna: Seit dem 1. Juli ist Torsten Uhlig neuer Vorstandsvorsitzender der Signal Iduna-Gruppe. Er übernimmt die Position von Ulrich Leitermann, der nach mehr als zwölf Jahren an der Spitze des Versicherungsunternehmens ausscheidet. Zugleich wurde Alexandra Markovic-Sobau zur neuen Vorständin für Vertrieb und Marketing berufen. Mit der Neubesetzung verjüngt Signal Iduna das Vorstandsteam und stellt die Weichen für die Strategie „MOMENTUM 2030“, die auf weiteres Wachstum in den Zielgruppen Handwerk, Handel und Öffentlicher Dienst ausgerichtet ist. Vom Hype zum Standard: Schadenökosysteme auf dem Vormarsch Schadenökosysteme entwickeln sich zunehmend vom Trend zum strategischen Instrument: Laut einer Studie von Verisk und den Versicherungsforen Leipzig planen rund 70 % der Versicherer und über 60 % der Dienstleister eine Beteiligung an solchen vernetzten Systemen. Ziele: Effizienzsteigerung, Kostenreduktion und bessere Kundenerfahrung. Dr. Philipp Scharner übernimmt Geschäftsfeld Mobilität bei der Bayerischen Die Versicherungsgruppe die Bayerische besetzt eine Schlüsselposition neu: Zum 1. Juli übernimmt Dr. Philipp Scharner die Leitung des Geschäftsfelds Mobilität. Er folgt auf Andreas Buhre, der das Unternehmen zum Jahresende verlässt. Scharner bringt als promovierter Volkswirt strategische Expertise und Erfahrung in der Steuerung der Unternehmensgruppe mit. Der Bereich Mobilität steht angesichts von Schadeninflation, Reparaturkosten und datengetriebener Modelle vor großen Herausforderungen. Ergo übernimmt Next Insurance vollständig Die Ergo Group hat die vollständige Übernahme des US-Digitalversicherers Next Insurance abgeschlossen. Mit dem Einstieg in den US-Markt stärkt Ergo ihre Position im KMU-Segment. Die Transaktion erfolgte auf Basis einer Bewertung von 2,6 Mrd. $. Next Insurance bleibt als technologiegetriebene Marke erhalten. Baloise erweitert gewerbliche Sachversicherung Mehr Schutz für KMU: Baloise verbessert ihre gewerbliche Sachversicherung mit neuen Leistungen wie dem Verzicht auf den Einwand der groben Fahrlässigkeit bis 100.000 EUR, höheren Sublimits für Seng- und Schwelschäden sowie neuen Bausteinen für Elektronik und Werkverkehr. Auch der digitale Abschluss über Thinksurance ist möglich.

Der DAX rutscht um 236 Punkte ab – exakt wie der MDAX. Handelskonflikte mit den USA bremsen die Börsen. Tesla fällt 7 %, nachdem Trump Elon Musk frontal angreift. Fed-Chef Powell dämpft die Zinshoffnungen. Shell testet neues Strompreis-Modell, Merck kauft für 3 Mrd. €, Diehl wächst mit Rüstung. Heiko Thieme bleibt gelassen, Philipp Vorndran predigt Sachwerte. Alle Interviews und Märkte jetzt im Börsenradio to go Podcast. Jetzt GRATIS Eintrittskarte sichern für die Rohstoffmesse München am 3+4. Oktober: https://www.rohstoffmesse-muenchen.de

Nasdaq, S&P 500 und Dow Jones starten je +0,5 % in die Woche - befeuert von Zinshoffnungen und Entspannung im Welthandel. Der DAX hingegen verliert nach Gewinnmitnahmen 0,5 % und schließt bei 23.910 Punkten. Auch der EuroStoxx50 gibt um 0,3 % nach. Die EZB will künftig flexibler auf Inflationsabweichungen reagieren. Gold gewinnt als sicherer Hafen wieder an Glanz, +0,6 % auf 3.284 Dollar. Firmen im Fokus: Lufthansa darf trotz Bedenken bei AirBaltic einsteigen. Siemens holt KI-Chef von Amazon. Mercedes meldet erfreulichen Auftragseingang beim E-CLA. Moderna überzeugt mit Grippeimpfstoff, Aktie +5 %. Inmune Bio crasht mit Alzheimer-Studie. Abbvie kauft Capstan für 2,1 Mrd. $. Home Depot übernimmt GMS für 5,5 Mrd. $. KLP verkauft Thyssenkrupp-Aktien wegen Israel-Geschäften. 1&1 senkt Ebitda-Prognose auf 545 Mio. €. Brainlab-Börsengang wohl bei 80 €. Dürr verkauft Umwelttechnik für 250 Mio. €. Börsenweisheit des Tages:"Die vier teuersten Worte an der Börse sind: Dieses Mal ist alles anders." - Sir John Templeton. In den Interviewsheute: Good bye, Dollar! Kathrin Eichler: "Der Favoritenwechsel findet statt. Im Depot: Home Bias mit Rüstung und Bausektor". Carmen Bandt über kapitale Fehler und individuelle Vorsorge-Kalkulation: "Auch ab 50 kann ich noch eine Menge machen". Heiko Böhmer auf dem V-Bank-Vermögenstag: "Gold: Nach so einem Run ist dann auch einmal Feierabend" - Smallcaps!

Hier geht's zum Private-Equity-Angebot von Scalable Capital: https://de.scalable.capital/private-equity Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Tour de France und Lacrosse geht an Börse. OpenAI-Mitarbeiter gehen zu Meta. Tesla kriegt Druck von Xiaomi. Micron kriegt Druck von NVIDIA. CoreWeave könnte Scientific kaufen. H&M mag den Sommer. Woran hängt der Erfolg von Henkel (WKN: 604840)? Und wo bleibt er? Ist NVIDIA (WKN: 918422) bald 6.000 Mrd. $ wert? Möglich ist es. Aber: Die Upside ist begrenzt. Und die Downside? Kapitalanlagen bergen Risiken. Es bestehen Liquiditätsbeschränkungen. Beachten Sie die spezifischen Produktinformationen. Diesen Podcast vom 27.06.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Die Themen im heutigen Versicherungsfunk Update sind: BVK kritisiert Gesetzentwurf zur EU-Verbraucherkreditrichtlinie Mit dem neuen § 34k GewO will das Bundesjustizministerium die EU-Verbraucherkreditrichtlinie in deutsches Recht umsetzen. Der BVK warnt vor wachsender Bürokratie: Pflicht zur Registereintragung und neue Sachkundeprüfung belasteten vor allem kleinere Vermittlerbetriebe. Eine „Alte-Hasen-Regelung“ fehlt. BVK-Präsident Michael H. Heinz fordert eine praxistauglichere Umsetzung. Sichere Lkw-Parkplätze: Versicherer schlagen Alarm Jeder dritte Frachtdiebstahl passiert beim Parken – mit Millionenschäden für Wirtschaft und Versicherer. Der GDV fordert deshalb mehr gesicherte Lkw-Parkplätze entlang europäischer Fernstraßen. Laut Jörg Asmussen seien „rund um die Uhr bewachte, eingezäunte Plätze mit Zugangskontrollen“ nötig, um Fahrer und Ware besser zu schützen. Alle 20 Minuten wird in Deutschland Ladung gestohlen, der jährliche Schaden liegt bei über 2 Mrd. Euro. WGV beruft Anja Emde in den Vorstand Zum 1. Juli 2025 wird Anja Emde neues Vorstandsmitglied der WGV Versicherung, der WGV-Versicherung AG und der WGV-Lebensversicherung AG. Sie folgt auf Ralf Pfeiffer, der zum 30. Juni 2025 in den Ruhestand tritt. Emde übernimmt unter anderem die Verantwortung für den Kommunalvertrieb, die Lebensversicherung und den Personalbereich. Sie ist zudem Ausgliederungsbeauftragte und Geldwäschebeauftragte nach § 4 GwG. HDI Global beruft Dr. Christian Wegener zum Head of Investment Management Dr. Christian Wegener hat zum 15. Juni 2025 die Leitung des Investment Managements bei HDI Global SE übernommen. Er folgt auf Thorsten Wölbern, der nach 15 Jahren neue Aufgaben im Unternehmen übernimmt. Wegener bringt internationale Erfahrung aus Stationen bei HSBC und AXA mit. Ziel ist es, die risikoadjustierte Rendite zu optimieren und globale Absicherungsprozesse weiterzuentwickeln. Metzler übernimmt Nürnberger Pensionsfonds Die Metzler Pension Management GmbH hat die Nürnberger Pensionsfonds AG übernommen. Seit dem 11. Juni 2025 firmiert sie unter dem Namen Metzler Mittelstands Pensionsfonds AG (MMPF). Mit Kapitalanlagen von 315 Millionen Euro, rund 700 Trägerunternehmen und über 3.500 Versorgungsverhältnissen baut Metzler sein bAV-Angebot gezielt für kleine und mittlere Unternehmen aus. Krank im Urlaub: Auslandskrankenversicherung kann tausende Euro sparen Ein Tag im Krankenhaus im Ausland kostet durchschnittlich 2.600 Euro – ein Rücktransport aus Spanien bis zu 30.000 Euro. Das zeigt eine Auswertung von Finanztip. Gute Auslandskrankenversicherungen gibt es bereits ab 10 Euro pro Jahr. Laut Finanztip sollten Reisende auf Leistungen wie Rücktransport bei „medizinischer Sinnhaftigkeit“ und Such- und Bergungskosten von mindestens 5.000 Euro achten. In einem aktuellen Test wurden entsprechende Tarife identifiziert. Wichtig ist auch die richtige Vorbereitung: Versicherungsunterlagen griffbereit halten, Belege sammeln und Rechnungen zügig einreichen.

Was passiert, wenn ein Karriere-Zufall den Weg von der Business School in London über MTV, McKinsey und Zalando bis ins Traditionsunternehmen OTTO ebnet – und aus einem Digital-Passionisten ein Vorreiter für KI im E-Commerce wird?In dieser Folge von „How to Hack“ spricht Carsten mit Dr. Boris Ewenstein, Bereichsvorstand Retail & Marketplace bei OTTO, über seinen unkonventionellen Werdegang und seine Mission, OTTO zum „best-in-class“ KI-gesteuerten Marktplatz zu transformieren.Die beiden sprechen außerdem über:Glückliche Zufälle als Karriere-Kompass: Von Sozialwissenschaften zur Top-Beratung und Plattform-ÖkonomieTransformation als Unternehmens-DNA: Lessons aus sechs Jahren Afrika-Geschäft und McKinseySkalierung im E-Commerce: 5 Mrd. zu 15 Mrd. GMV bei Zalando – und OTTO als Generalist mit 18 Mio. ArtikelnDie vier Hygienefaktoren: Basis-Performance, Beratung, Brand-Love & Best-ServiceKI als Gamechanger: Wie Agenten-Recherche und Beratung neu definiert werdenVision 2028: Persönliche Assistenten, Loyalty-Revolution und hyper-personalisierte Shopping-JourneysEin spannender Talk über Casual Karriere-Schicksal, Plattform-Strategie und die Frage, wie man 75 Jahre Handels-Tradition in eine Tech-Dekade rettet.

Thu, 26 Jun 2025 17:03:00 +0000 https://jungeanleger.podigee.io/2368-kapitalmarkt-stimme-at-daily-voice-177-365-sorge-um-gunstige-absicherungsprodukte-fur-kapitalanlagen 37de3d196a60829340c9eeca58366a0a kapitalmarkt-stimme.at daily voice 177/365: Die deutsche Finanzmarktaufsicht BaFin hat ein Problem mit Turbo-Zertifikaten, weil diese nach deren Berechnungen Anlegern seit 2019 einen Verlust von 3,4 Mrd. Euro gebracht haben sollen. Ich meine: Man muss diese Produkte immer im Portfoliokontext sehen, denn gerade in Phasen steigender Notierungen kann man sich über Turbos zb extrem günstig absichern. Dies natürlich nicht in der Hoffnung, dass es wirklich runter geht. Ich sehe es so, wie wenn man sein Haus gegen Feuer versichert, dies hoffentlich auch nicht in der Hoffnung, dass es abbrennt. Also schwieriges Thema. Mehr im Podcast. Mail: Anhoerung- Produktintervention@bafin.de Unser Ziel: Kapitalmarkt is coming home. Täglich zwischen 19 und 20 Uhr. kapitalmarkt-stimme.at daily voice Playlist auf spotify: http://www.kapitalmarkt-stimme.at/spotify http://www.kapitalmarkt-stimme.at Musik: Steve Kalen: https://open.spotify.com/artist/6uemLvflstP1ZerGCdJ7YU Playlist 30x30 (min.) Finanzwissen pur: http://www.audio-cd.at/30x30 Bewertungen bei Apple (oder auch Spotify) machen mir Freude: http://www.audio-cd.at/apple http://www.audio-cd.at/spotify 2368 full no Christian Drastil Comm. 158

Dr. Vamsi Velcheti and Dr. Nate Pennell discuss novel treatment approaches in small cell and non-small cell lung cancer that were featured at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Vamsi Velcheti: Hello, I'm Dr. Vamsi Velcheti, your guest host of the ASCO Daily News Podcast. I'm a professor of medicine and chief of hematology and oncology at the Mayo Clinic in Jacksonville, Florida. The 2025 ASCO Annual Meeting featured some exciting advancements in small cell lung cancer, targeted therapies for non-small cell lung cancer, and other novel [treatment] approaches. Today, I'm delighted to be joined by Dr. Nate Pennell to discuss some of the key abstracts that are advancing the lung cancer field. Dr. Pennell is the co-director of the Cleveland Clinic Lung Cancer Program and also the vice chair of clinical research at the Taussig Cancer Institute. Our full disclosures are available in the transcript of this episode. Nate, it's great to have you back on the podcast. Thanks so much for being here. Dr. Nate Pennell: Thanks, Vamsi. Always a pleasure. Dr. Vamsi Velcheti: Let's get started, and I think the first abstract that really caught my attention was Abstract 8516, “The Randomized Trial of Relevance of Time of Day of Immunotherapy for Progression-Free and Overall Survival in Patients With Non-Small Cell Lung Cancer.” What are your thoughts about this, Nate? Dr. Nate Pennell: I agree. I thought this was one of the most discussed abstracts, certainly in the lung cancer session, but I think even outside of lung cancer, it got some discussion. So, just to put this in perspective, there have been a number of publications that have all been remarkably consistent, and not just in lung cancer but across multiple cancer types, that immunotherapy, immune checkpoint inhibitors, are commonly used. And all of them have suggested, when looking at retrospective cohorts, that patients who receive immune checkpoint inhibitors earlier in the day – so in the morning or before the early afternoon – for whatever reason, appear to have better outcomes than those who get it later in the day, and this has been repeated. And I think many people just sort of assumed that this was some sort of strange association and that there was something fundamentally different from a prognostic standpoint in people who came in in the morning to get their treatment versus those who came later in the afternoon, and that was probably the explanation. The authors of this randomized trial actually decided to test this concept. And so, about 210 patients with previously untreated advanced non-small cell lung cancer were randomly assigned to get chemo and immune checkpoint inhibitor – either pembrolizumab or sintilimab – and half of them were randomly assigned to get the treatment before 3 PM in the afternoon, and half of them were assigned to get it after 3 PM in the afternoon. And it almost completely recapitulated what was seen in the retrospective cohorts. So, the median progression-free survival in those who got earlier treatment was 13.2 months versus only 6.5 months in those who got it later in the day. So, really enormous difference with a hazard ratio of 0.43, which was statistically significant. And perhaps even more striking, the median overall survival was not reached in the early group versus 17.8 months in the late group with a hazard ratio of 0.43, also highly statistically significant. Even the response rate was 20% higher in the early patients; 75% response rate compared to 56% in the late-time-of-day patients. So very consistent across all measures of efficacy with pretty good matched characteristics across the different groups. And so, I have to tell you, I don't know what to make of this. I certainly was a skeptic about the retrospective series, but now we have a prospective randomized trial that shows essentially the same thing. So, maybe there is a difference between getting treated in the morning, although I have yet to hear someone give a very good mechanistic explanation as to why this would be. What were your thoughts on this? Dr. Vamsi Velcheti: It's indeed fascinating, Nate, and I actually think this was a very interesting abstract. Really, I was caught off guard looking at the data. I mean, if it were a drug, we would be so excited, right? I mean, with those kind of survival benefits. I don't know. I think circadian rhythm probably has something to do with it, like different cytokine profiles at the time of administration. I mean, who knows? But I think it's a randomized trial, and I think I would expect to see a mad rush for treatment appointments early in the morning given this, and at least I want my patients to come in first thing in the morning. It'll be interesting to see. Dr. Nate Pennell: It's important to point out that in this study, everyone got chemo and immunotherapy. And, at least in our cancer center, most patients who are getting platinum-doublet chemotherapy and immunotherapy actually do get treated earlier in the day already, just because of the length of the infusion appointment that's needed. So it really is oftentimes people getting single-agent immunotherapy who are often getting the later, shorter visits. But if you have a choice, I think it would be very reasonable to have people treated earlier in the day. And I do think most of the impressions that I got from people about this is that they would like to see it reproduced but certainly well worth further investigation. And I personally would like to see more investigation into what the rationale would be for this because I still can't quite figure out, yes, if you got it at, say, you know, 5 PM, that's later in the day and I can understand that maybe your immune system is somewhat less receptive at that point than it would be in the morning. But because these checkpoint inhibitors have such long half-lives, it's still in your system the next morning when your immune system is supposedly more receptive. So I don't quite understand why that would be the case. Well, let's move on to the next study. I would like to hear your thoughts on Abstract 8515, “Plasma-Guided, Adaptive First-Line Chemoimmunotherapy for Non-Small Cell Lung Cancer.” Dr. Vamsi Velcheti: Yeah, this was another abstract that seems to be really interesting in my opinion. I think there's kind of a lot of emphasis lately on ctDNA and MRD-based assays to monitor disease. In the lung cancer space, we haven't had a lot of clinical trials looking at this prospectively, and this was one of those pilot studies where they looked at circulating free DNA (cfDNA)-based response-adaptive strategy for frontline patients who are PD-L1 positive. So, patients started with pembrolizumab monotherapy, and based on plasma molecular response after 2 cycles, those patients without response received early treatment intensification with a platinum doublet. So the approach essentially was to reduce the chemotherapy exposure in patients who respond to immunotherapy. And only about 17.5% of the patients on the trial received chemotherapy based on lack of molecular response. So, in this trial, what they found was patients with the cfDNA response had a markedly improved PFS of 16.4 months versus 4.8 months. So essentially, like, this is a really nice study to set a foundation on which we have to do larger studies to incorporate molecular markers trying to look at cfDNA response to inform treatment strategy, either escalation or de-escalation strategies. So, I thought it was a very interesting study. Dr. Nate Pennell: Yeah. I mean, we always have this question for patients, “Should they get immunotherapy alone or combined with chemo?” and I think this certainly is intriguing, suggesting that there may be ways you can monitor people and perhaps rescue those that aren't going to respond to single agent. I'd like to see a randomized trial against, you know, this strategy, perhaps against everyone getting, say, chemoimmunotherapy or make sure that you're not potentially harming people by doing this strategy. But I agree, it's time to move beyond just observing that cell-free DNA is prognostic and important and start using it to actually guide treatment. Dr. Vamsi Velcheti: Yeah, and I would just caution though, like, you know, I think we need more data, but, however, it's certainly a very interesting piece of data to kind of help inform future trials. So, there was another abstract that caught my attention, and I think this would be a very interesting abstract in the EGFR space. Abstract 8506, "Patritumab Deruxtecan (HER3-DXd) in Resistant EGFR-Mutant Advanced Non-Small Cell Lung Cancer Patients After Third-Generation EGFR TKI," it's the HERTHENA-Lung02 study. What do you think about the results of this study? Dr. Nate Pennell: Yeah, this was, I would say, very widely anticipated and ultimately a little disappointing, despite being a positive trial. So, these are patients with EGFR-mutant non-small cell lung cancer who have progressed after a third-generation EGFR TKI like osimertinib. This is really an area of major unmet need. We do have drugs like amivantamab in this space, but still definitely an area where essentially patients move from having a highly effective oral therapy to being in the realm of chemotherapy as their best option. So, this HER3 antibody-drug conjugate, patritumab deruxtecan, had some good single-arm data for this. And we're sort of hoping this would become an available option for patients. This trial was designed against platinum-doublet chemotherapy in this setting and with a primary endpoint of progression-free survival. And it actually was positive for improved progression-free survival compared to chemo with a hazard ratio of 0.77. But when you look at the medians, you can see that the median PFS was only 5.8 versus 5.4 months. It was really a modest difference between the two arms. And on the interim analysis, it appeared that there will not be a difference in overall survival between the two arms. In fact, the hazard ratio at the interim analysis was 0.98 for the two arms. So based on this, unfortunately, the company that developed the HER3-DXd has withdrawn their application to the FDA for approval of the drug, anticipating that they probably wouldn't get past approval without that overall survival endpoint. So, unfortunately, probably not, at least for the near future, going to be a new option for these patients. Dr. Vamsi Velcheti: Yeah, I think this is a space that's clearly an unmet need, and this was a big disappointment, I should say. I think all of us were going into the meeting anticipating some change in the standard of care here. Dr. Nate Pennell: Yeah, I agree. It was something that I was telling patients, honestly, that I was expecting this to be coming, and so now, definitely a bit of a disappointment. But it happens and, hopefully, it will still find perhaps a role or other drugs with a similar target. Certainly an active area. Well, let's leave the EGFR-mutant space and move into small cell. There were a couple of very impactful studies. And one of them was Abstract 8006, “Lurbinectedin Plus Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer, Primary Results from the Phase III IMforte Trial.” So, what was your impression of this? Dr. Vamsi Velcheti: Yeah, I think this is definitely an interesting study, and small cell, I remember those days when we had barely any studies of small cell at ASCO, and now we have a lot of exciting developments in the small cell space. It's really good to see. The IMforte trial is essentially like a maintenance lurbinectedin trial with atezolizumab maintenance. And the study was a positive trial. The primary endpoint was a PFS, and the study showed improvement in both PFS and OS with the addition of lurbinectedin to atezolizumab maintenance. And definitely, it's a positive trial, met its primary endpoint, but I always am a little skeptical of adding maintenance cytotoxic therapies here in this setting. In my practice, and I'd like to hear your opinion, Nate, most patients with small cell after 4 cycles of a platinum doublet, they're kind of really beaten up. Adding more cytotoxic therapy in the maintenance space is going to be tough, I think, for a lot of patients. But also, most importantly, I think this rapidly evolving landscape for patients with small cell lung cancer with multiple new, exciting agents, actually like some FDA-approved like tarlatamab, also like a lot of these emerging therapeutics like I-DXd and other ADCs in this space. You kind of wonder, is it really optimal strategy to bring on like another cytotoxic agent right after induction chemotherapy, or do you kind of delay that? Or maybe have like a different strategy in terms of maintenance. I know that the tarlatamab maintenance trial is probably going to read out at some point too. I think it's a little challenging. The hazard ratio is also 0.73. As I said, it's a positive trial, but it's just incremental benefit of adding lurbi. And also on the trial, we need to also pay attention to the post-progression second-line treatments, number of patients who received tarlatamab or any other investigational agents.  So I think it's a lot of questions still. I'm not quite sure I'd be able to embrace this completely. I think a vast majority of my patients might not be eligible anyway for cytotoxic chemotherapy maintenance right away, but yeah, it's tough. Dr. Nate Pennell: Yeah. I would call this a single and not a home run. It definitely is real. It was a real overall survival benefit. Certainly not surprising that a maintenance therapy would improve progression-free survival. We've known that for a long time in small cell, but first to really show an overall survival benefit. But I completely agree with you. I mean, many people are not going to want to continue further cytotoxics after 4 cycles of platinum-doublet chemo. So I would say, for those that are young and healthy and fly through chemo without a lot of toxicity, I think certainly something worth mentioning. The problem with small cell, of course, is that so many people get sick so quickly while on that observation period after first-line chemo that they don't make it to second-line treatment. And so, giving everyone maintenance therapy essentially ensures everyone gets that second-line treatment. But they also lose that potentially precious few months where they feel good and normal and are able to be off of treatment. So, I would say this is something where we're really going to have to kind of sit and have that shared decision-making visit with patients and decide what's meaningful to them. Dr. Vamsi Velcheti: Yeah, I agree. The next abstract that was a Late-Breaking Abstract, 8000, “Overall Survival of Neoadjuvant Nivolumab Plus Chemotherapy in Patients With Resectable Non-Small Cell Lung Cancer in CheckMate-816.” This was a highly anticipated read-out of the OS data from 816. What did you make of this abstract? Dr. Nate Pennell: Yeah, I thought this was great. Of course, CheckMate-816 changed practice a number of years ago when it first reported out. So, this was the first of the neoadjuvant or perioperative chemoimmunotherapy studies in resectable non-small cell lung cancer. So, just to review, this was a phase 3 study for patients with what we would now consider stage II or stage IIIA resectable non-small cell lung cancer. And they received three cycles of either chemotherapy or chemotherapy plus nivolumab, and that was it. That was the whole treatment. No adjuvant treatment was given afterwards. They went to resection. And patients who received the chemoimmunotherapy had a much higher pathologic complete response rate and a much better event-free survival. And based on this, this regimen was approved and, I think, at least in the United States, widely adopted.  Now, since the first presentation of CheckMate 816, there have been a number of perioperative studies that have included an adjuvant component of immunotherapy – KEYNOTE-671, the AEGEAN study – and these also have shown improved outcomes. The KEYNOTE study with pembrolizumab also with an overall survival benefit. And I think people forgot a little bit about CheckMate-816. So, this was the 5-year overall survival final analysis. And it did show a statistically and, I think, clinically meaningful difference in overall survival with the 3 cycles of neoadjuvant chemo-nivo compared to chemo with a hazard ratio of 0.72. The 5-year overall survival of 65% in the chemo-IO group versus 55% with the chemo alone. So a meaningful improvement. And interestingly, that hazard ratio of 0.72 is very similar to what was seen in the peri-operative pembro study that included the adjuvant component. So, very much still relevant for people who think that perhaps the value of those neoadjuvant treatments might be really where most of the impact comes from this type of approach. They also gave us an update on those with pathologic complete response, showing really astronomically good outcomes. If you have a pathologic complete response, which was more than a quarter of patients, the long-term survival was just phenomenal. I mean, 95% alive at 5 years if they were in that group and suggesting that in those patients at least, the adjuvant treatment may not be all that important.  So, I think this was an exciting update and still leaves very much the open question about the importance of continuing immunotherapy after surgery after the neoadjuvant component. Dr. Vamsi Velcheti: Yeah, I completely agree, Nate. I think the million-dollar question is: “Is there like a population of patients who don't have complete response but like maybe close to complete response?” So, would you like still consider stopping adjuvant IO? I probably would not be comfortable, but I think sometimes, you know, we all have patients who are like very apprehensive of continuing treatments. So, I think that we really need more studies, especially for those patients who don't achieve a complete CR. I think trying to find strategies for like de-escalation based on MRD or other risk factors. But we need more trials in that space to inform not just de-escalation, but there are some patients who don't respond at all to a neoadjuvant IO. So, there may be an opportunity for escalating adjuvant therapies. So, it is an interesting space to watch out for. Dr. Nate Pennell: No, absolutely. Moving to KRAS-mutant space, so our very common situation in patients with non-small cell lung cancer, we had the results of Abstract 8500, “First-Line Adagrasib With Pembrolizumab in Patients With Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer” from the phase 2 portion of the KRYSTAL-7 study. Why was this an interesting and important study? Dr. Vamsi Velcheti: First of all, there were attempts to kind of combine KRASG12C inhibitors in the past with immune checkpoint inhibitors, notably sotorasib with pembrolizumab. Unfortunately, those trials have led to like a lot of toxicity, with increased especially liver toxicity, which was a major issue. This is a phase 2 study of adagrasib in combination with pembrolizumab, and this is a study in the frontline setting in patients with the G12C-mutant metastatic non-small cell lung cancer. And across all the PD-L1 groups, the ORR was 44%, and the median PFS was 11 months, comparable to the previous data that we have seen with adagrasib in this setting. So it's not like a major improvement in clinical efficacy. However, I think the toxicity profile that we were seeing was slightly better than the previous trials in combination with sotorasib, but you still have a fair amount of transaminitis even in the study. At this point, this is not ready for clinical primetime. I don't think we should be using sotorasib or adagrasib in the frontline or even in the second line in combination with checkpoint inhibitors. Combining these drugs with checkpoint inhibitors in the clinical practice might lead to adverse outcomes. So, we need to wait for more data like newer-generation G12C inhibitors which are also being studied in combination, so we'll have to kind of wait for more data to emerge in this space. Dr. Nate Pennell: I agree, this is not immediately practice changing. This is really an attempt to try to combine targeted treatment with immune checkpoint inhibitor. And I agree with you that, you know, it does appear to be perhaps a little bit better tolerated than some of the prior combinations that have tried in this space. The outcomes overall were not that impressive, although in the PD-L1 greater than 50%, it did have a better response rate perhaps than you would expect with either drug alone. And I do think that the company is focusing on that population for a future randomized trial, which certainly would inform this question better. But in the meantime, I agree with you, there's a lot of newer drugs that are coming along that potentially may be more active and better tolerated. And so, I'd say for now, interesting but we'll wait and see. Dr. Vamsi Velcheti: Yeah, so now moving back again to small cell. So, there was a Late-Breaking Abstract, 8008. This is a study of tarlatamab versus chemotherapy as second-line treatment for small cell lung cancer. They presented the primary analysis of the phase III DeLLphi-304 study. What do you think about this? Dr. Nate Pennell: Yeah, I thought this was really exciting. This was, I would say, perhaps the most important lung study that was presented. Tarlatamab is, of course, the anti-DLL3 bispecific T-cell engager compound, which is already FDA approved based on a prior single-arm phase II study, which showed a very nice response rate as a single agent in previously treated small cell lung cancer and relatively manageable side effects, although somewhat unique to solid tumor docs in the use of these bispecific drugs in things like cytokine release syndrome and ICANS, the neurologic toxicities. So, this trial was important because tarlatamab was approved, but there were also other chemotherapy drugs approved in the previously treated space. And so, this was a head-to-head second-line competition comparison between tarlatamab and either topotecan, lurbinectedin, or amrubicin in previously treated small cell patients with a primary endpoint of overall survival. So, a very well-designed trial. And it did show, I think, a very impressive improvement in overall survival with a median overall survival in the tarlatamab group of 13.6 months compared to 8.3 months with chemotherapy, hazard ratio of 0.6. And progression-free survival was also longer at 4.2 months versus 3.2 months, hazard ratio of 0.72. In addition to showing improvements in cancer-related symptoms that were improved in tarlatamab compared to chemotherapy, there was actually also significantly lower rates of serious treatment-related adverse events with tarlatamab compared to chemotherapy. So, you do still see the cytokine release syndrome, which is seen in most people but is manageable because these patients are admitted to the hospital for the first two cycles, as well as a significant number of patients with neurologic side effects, the so-called ICANS, which also can be treated with steroids. And so, I think based upon the very significant improvement in outcomes, I would expect that this should become our kind of standard second-line treatment since it seems to be much better than chemo. However, tarlatamab is definitely a new drug that a lot of places are not used to using, and I think a lot of cancer centers, especially ones that aren't tied to a hospital, may have questions about how to deal with the CRS. So, I'm curious your thoughts on that. Dr. Vamsi Velcheti: Yeah, thank you, Nate. And I completely agree. I think the data looked really promising, and I've already been using tarlatamab in the second-line space. The durability of response and overall, having used tarlatamab quite a bit - like, I participated in some of the early trials and also used it as standard of care - tarlatamab has unique challenges in terms of like need for hospitalization for monitoring for the first few treatments and make sure, you know, we monitor those patients for CRS and ICANS. But once you get past that initial administration and monitoring of CRS, these patients have a much better quality of life, they're off chemotherapy, and I think it's really about the logistics of actually administering tarlatamab and coordination with the hospital and administration in the outpatient setting. It's definitely challenging, but I think it definitely can be done and should be done given what we are seeing in terms of clinical efficacy here. Dr. Nate Pennell: I agree. I think hospital systems now are just going to have to find a way to be able to get this on formulary and use it because it clearly seems to be more effective and generally better tolerated by patients. So, should move forward, I think. Finally, there's an abstract I wanted to ask you about, Abstract 8001, which is the “Neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone in resectable epidermal growth factor receptor-mutated non-small cell lung cancer: The NeoADAURA Study”. And this is one that I think was also fairly highly anticipated. So, what are your thoughts? Dr. Vamsi Velcheti: You know, I wasn't probably surprised with the results, and I believe we were all expecting a positive trial, and we certainly were handed a positive trial here. It's a phase III trial of osimertinib and chemotherapy or osimertinib in the neoadjuvant space followed by surgery, followed by osimertinib. It's a global phase 3 trial and very well conducted, and patients with stage II to stage IIIB were enrolled in the study. And in the trial, patients who had a neoadjuvant osimertinib with or without chemotherapy showed a significant improvement in major pathologic response rates over chemotherapy alone. And the EFS was also positive for osimertinib and chemotherapy, osimertinib monotherapy as well compared to chemotherapy alone. So overall, the study met its primary endpoint, and I think it sheds light on how we manage our patients with early-stage lung cancer. I think osimertinib, we know that osimertinib is already FDA approved in the adjuvant space, but what we didn't really know is how was osimertinib going to work in the neoadjuvant space. And there are always situations, especially for stage III patients, where we are on the fence about, are these patients already close to being metastatic? They have, like, almost all these patients have micrometastatic disease, even if they have stage III. As we saw in the LAURA data, when you look at the control arm, it was like a very short PFS. Chemoradiation does nothing for those patients, and I think these patients have systemic mets, either gross or micrometastatic disease at onset. So, it's really important to incorporate osimertinib early in the treatment course. And I think, especially for the locally advanced patients, I think it's even more important to kind of incorporate osimertinib in the neoadjuvant space and get effective local control with surgery and treat them with adjuvant. I'm curious to hear your thoughts, Nate. Dr. Nate Pennell: I am a believer and have long been a believer in targeted adjuvant treatments, and, you know, it has always bothered me somewhat that we're using our far and away most effective systemic therapy; we wait until after they go through all their pre-op treatments, they go through surgery, then they go through chemotherapy, and then finally months later, they get their osimertinib, and it still clearly improves survival in the adjuvant setting. Why not just start the osimertinib as soon as you know that the patient has EGFR-mutant non-small cell lung cancer, and then you can move on to surgery and adjuvant treatment afterwards? And I think what was remarkable about this study is that all of these patients almost - 90% in each arm - went to surgery. So, you weren't harming them with the neoadjuvant treatment. And clearly better major pathologic response, nodal downstaging, event-free survival was better. But I don't know that this trial is ever going to show an overall survival difference between neoadjuvant versus just surgery and adjuvant treatment, given how effective the drug is in the adjuvant setting. Nonetheless, I think the data is compelling enough to consider this, certainly for our N2-positive, stage IIIA patients or a IIIB who might be otherwise surgical candidates. I think based on this, I would certainly consider that. Dr. Vamsi Velcheti: Yeah, and especially for EGFR, like even for stage IIIB patients, in the light of the LAURA study, those patients who do not do too well with chemoradiation. So you're kind of delaying effective systemic therapy, as you said, waiting for the chemoradiation to finish. So I think probably time to revisit how we kind of manage these locally advanced EGFR patients. Dr. Nate Pennell: Yep, I agree. Dr. Vamsi Velcheti: Nate, thank you so much for sharing your fantastic insights today on the ASCO Daily News Podcast. It's been an exciting ASCO again. You know, we've seen a lot of positive trials impacting our care of non-small cell lung cancer and small cell lung cancer patients. Dr. Nate Pennell: Thanks for inviting me, Vamsi. Always a pleasure to discuss these with you. Dr. Vamsi Velcheti: And thanks to our listeners for your time today. You will find links to all of the abstracts discussed today in the transcript of the episode. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, subscribe wherever you get your podcast. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:    Dr. Vamsi Velcheti   @VamsiVelcheti    Dr. Nathan Pennell   @n8pennell   Follow ASCO on social media:     @ASCO on Twitter     ASCO on Facebook     ASCO on LinkedIn   ASCO on BlueSky   Disclosures:   Dr. Vamsi Velcheti:   Honoraria: ITeos Therapeutics   Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus   Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline   Dr. Nathan Pennell:     Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron    Research Funding (Inst): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi 

Ein Gerichtsbeschluss zwingt OpenAI, Werbematerialien zu einem Deal mit Jony Ive vorübergehend zurückzuziehen. Die ehemalige CTO von OpenAI, Murati, bereitet sich darauf vor, mit seinem Startup in den Wettbewerb gegen seinen früheren Arbeitgeber zu treten, während im Silicon Valley kleine Teams den neuen Maßstab für Erfolg setzen. Disney geht rechtlich gegen Midjourney vor, um seine Charaktere vor unautorisierter KI-Nutzung zu schützen, und Masayoshi Son plant ein milliardenschweres KI-Roboterzentrum in Arizona. Nik Storonsky von Revolut könnte eine Auszahlung im Stil von Elon Musk erhalten, und Derek Mobley untersucht die Rolle von Algorithmen bei der Ablehnung von Bewerbungen. Deutschland und Italien stehen unter Druck, ihre Goldreserven aus den USA zurückzuführen. Novo Nordisk beendet die Partnerschaft mit Hims & Hers wegen Nachahmerprodukten. Blue Origin expandiert nach Europa, Elon Musk steht erneut im Zentrum rechtlicher Auseinandersetzungen, und Tesla testet fahrerlose Robotaxis in Austin.  Unterstütze unseren Podcast und entdecke die Angebote unserer Werbepartner auf ⁠⁠⁠⁠⁠doppelgaenger.io/werbung⁠⁠⁠⁠⁠. Vielen Dank!  Philipp Glöckler und Philipp Klöckner sprechen heute über: (00:00:00) OpenAI Jony Ive Gerichtsbeschluss  (00:08:20) Ex OpenAI CTO Startup (00:16:00) KI Tiny Team  (00:25:50) Disney KI Klage (00:30:50) SoftBank Robotik Investition (00:34:40) Revolut Nik Storonsky Aktienanteile (00:37:00) Bewerbungen Algorithmen  (00:42:15) Goldreserven Deutschland (00:46:00) Novo Nordisk Hims & Hers Partnerschaftsende (00:47:30) Google Workspace OpenAI (00:57:20) Schmuddelecke Shownotes OpenAI zieht Werbematerialien zu Jony Ive zurück – techcrunch.com OpenAIs erstes KI-Gerät mit Jony Ive ist kein Wearable – theverge.com Wie Muratis Startup gegen OpenAI konkurrieren will – theinformation.com KI leitet die 'Tiny Team'-Ära im Silicon Valley ein – bloomberg.com Disneys Kampagne zum Schutz von Darth Vader vor KI – bloomberg.com SoftBanks Masayoshi Son plant KI-Roboter-Hub in Arizona – bloomberg.com Apple erwägt Kauf von KI-Startup Perplexity – bloomberg.com Meta verhandelt mit Startup Runway über KI-Recruiting – bloomberg.com Revolut-Chef vor Musk-ähnlicher Auszahlung bei $150 Mrd. Bewertung – ft.com Millionen von Lebensläufen scheitern an Bots. Ein Mann will herausfinden, warum. – wsj.com Deutschland und Italien sollen 245 Mrd. Dollar Gold aus den USA zurückholen – ft.com Texas mit Bitcoin-Reserven – decrypt.co Novo Nordisk beendet Partnerschaft mit Hims & Hers wegen Nachahmer-Wegovy-Medikamenten – on.ft.com OpenAI Google Workspace – theinformation.com Jeff Bezos' Raumfahrtunternehmen: Blue Origin eröffnet Europazentrale in Luxemburg – today.rtl.lu Elon Musk nutzt keinen Computer – wired.com Tesla startet Robotaxi-Fahrten in Austin – techcrunch.com Teslas Robotaxi ist live: erste Reaktionen. – theverge.com Die großen Technologieneuigkeiten von Octopus und BYD, die ignoriert wurden – linkedin.com DeepSeek unterstützt Chinas Militär, umgeht Exportkontrollen – reuters.com Tesla Robotaxi-Vorfälle ziehen Aufmerksamkeit der US-Sicherheitsbehörde auf sich – bloomberg.com Tesla droht Strafe in Frankreich wegen irreführender Aussagen – ft.com Elon Musk besorgt über Realitätseinfluss auf "Grok" KI – futurism.com Cloudflare-CEO: Nutzer überprüfen Quellen von KI-Chatbots nicht – engadget.com

In dieser Folge:Warum wechselt Florian Wirtz nicht zum FC Bayern, sondern für ein Gesamtvolumen von 300 Millionen zum FC Liverpool? Welche Rolle spielen dabei Infrastruktur, familiäre Entscheidungen und wirtschaftliche Weitsicht?

Die Themen im heutigen Versicherungsfunk Update sind: § 34k GewO kommt: Vermittlung von Ratenkrediten wird reguliert Ab dem 20. November 2026 benötigen Vermittler von Raten- und Verbraucherkrediten eine eigene Erlaubnis nach § 34k GewO. Der Gesetzentwurf sieht eine neue IHK-Sachkundeprüfung, Weiterbildungspflichten und Registereintragungen vor – eine „Alte-Hasen-Regelung“ entfällt. Der AfW fordert ausreichende Prüfungskapazitäten und kritisiert Ausnahmen für Absatzfinanzierer scharf. IDEAL bekommt neuen Kapitalanlage-Vorstand Marc Schwetlik übernimmt ab Oktober 2025 das Kapitalanlageressort bei der IDEAL Versicherungsgruppe. Er folgt auf Karlheinz Fritscher, der nach 20 Jahren im Unternehmen zum Jahresende ausscheidet. Schwetlik war zuvor CIO der Bayerischen. DEVK wächst stark – Rekord im Neugeschäft, Rückversicherung treibt Konzern Die DEVK steigert 2024 ihre Beitragseinnahmen um 12,4 % auf 5,4 Mrd. EUR. Das Neugeschäft erreicht mit 1,1 Mrd. EUR ein Rekordniveau. Besonders kräftig wuchs die Kfz-Versicherung (+21,3 %). Die Rückversicherung bleibt Hauptwachstumstreiber, das Kapitalanlageergebnis legt um 16,9 % zu. Für 2025 erwartet der Konzern weiteres Wachstum, u. a. durch neue Produkte in der Altersvorsorge. Pangaea Life setzt auf Walnut Live für digitalen Fondsvertrieb Die Pangaea Life GmbH nutzt ab sofort die Vertriebsplattform Walnut Live für den digitalen Vertrieb ihres Anlageprodukts „Pangaea Life Institutional Co-Invest US Residential“. Damit können Finanzberater das nachhaltige US-Immobilieninvestment vollständig digital zeichnen. Walnut Live bietet Funktionen wie Videoberatung, Co-Browsing und CRM. Laut Anbieter wurden durch die Plattform bereits 128.000 Seiten Papier und 350.000 Fahrtkilometer eingespart. ERGO stärkt Geschäft in Nordeuropa Die ERGO Group AG hat ihre dänische Reiseversicherungsgesellschaft und den norwegischen Krankenversicherer zur neuen ERGO Forsikring A/S fusioniert. Mit Sitz in Kopenhagen soll das pan-nordische Unternehmen Wachstum in Dänemark, Norwegen und Schweden vorantreiben. Tarifliche Ausbildungsvergütungen steigen deutlich Im Ausbildungsjahr 2024/25 steigen die tarifvertraglichen Ausbildungsvergütungen um durchschnittlich 6,4 %. In vielen Branchen liegen die Einstiegsvergütungen inzwischen über 1.000 EUR im Monat – besonders hoch in Pflege, Banken und Industrie. Stärkster Zuwachs mit +18,6 % im Backhandwerk. Hintergrund ist der zunehmende Fachkräftemangel.

Dr. Vivek Subbiah returns for another edition of Vivek's Takes, offering his expert insights on the standout science from the 2025 ASCO Annual Meeting. He breaks down key developments including trispecific antibodies, the growing role of radioligand therapies, a new standard of care in small cell lung cancer, and paradigm-shifting data in adjuvant therapy for colorectal cancer. The discussion also highlights a long-term exercise intervention, adjuvant vaccine studies, ctDNA and MRD integration, resistance mechanisms, artificial intelligence, and other emerging trends shaping the future of oncology. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Aktien hören ist gut. Aktien kaufen ist besser. Bei unserem Partner Scalable Capital geht's unbegrenzt per Trading-Flatrate oder regelmäßig per Sparplan. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Circle boomt und wir checken's nicht. Brad Jacobs und QXO streiten sich mit Home Depot um GMS. Maserati könnt ihr kaufen. Apple könnte Perplexity kaufen. Wix hat Base44 gekauft. Softbank, Foxconn & NVIDIA planen Zukunft. Trump greift den Iran an. Der Markt für Lachs soll bis 2034 über 40 Mrd. $ schwer sein. Schon heute kommt das Angebot der extrem hohen Nachfrage kaum hinterher. Akva (WKN: A0LEQU) will das lösen. 7% Dividende bei einer Biotech-Wette? Alexandria Real Estate (WKN: 907179) macht's möglich. Diesen Podcast vom 23.06.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Dr. John Sweetenham and Dr. Marc Braunstein highlight top research on hematologic malignancies from the 2025 ASCO Annual Meeting, including abstracts on newly diagnosed chronic phase CML, relapsed B-cell lymphoma, and multiple myeloma. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. On today's episode, we'll be discussing promising advances in newly diagnosed chronic phase CML, relapsed B-cell lymphoma, multiple myeloma, and other hematologic malignancies that were presented at the 2025 ASCO Annual Meeting. Joining me for this discussion is Dr. Marc Braunstein, a hematologist and oncologist at the NYU Perlmutter Cancer Center. Our full disclosures are available in the transcript of this episode.  Marc, there were some great studies in the heme space at this year's Annual Meeting, and it's great to have you back on the podcast to highlight some of these advances. Dr. Marc Braunstein: Yes, I agree, John, and thank you so much for inviting me again. It's great to be here.  Dr. John Sweetenham: Let's start out with Abstract 6501. This was a study that reported on the primary endpoint results of the phase 3B ASC4START trial, which assessed asciminib versus nilotinib in newly diagnosed chronic phase CML. And the primary endpoint of this, as you know, was time to treatment discontinuation because of adverse events. Can you give us your insights into this study? Dr. Marc Braunstein: Absolutely. So, like you mentioned, you know, asciminib is an allosteric inhibitor of the BCR-ABL kinase that has activity in CML, and that includes patients with the T315I mutation that confers resistance to first- and second-generation TKIs. So, the ASC4FIRST study, which was published last year in the New England Journal of Medicine, showed superior efficacy of asciminib compared to investigator-selected first- or second-generation TKIs, actually leading to the FDA approval of asciminib in first-line CML. So, the authors of that study presented data at this year's ASCO meeting from the phase 3 ASC4START comparing safety and time to discontinuation due to adverse events of asciminib versus nilotinib, a second-generation TKI. So, 568 patients with newly diagnosed CML were randomized one-to-one to once-daily asciminib or twice-daily nilotinib. So, at a median follow-up of 9.7 months, about 11% in the asciminib group and 17% in the nilotinib group discontinued treatment, with significantly fewer discontinuations with asciminib due to adverse events. There was also a secondary endpoint of major molecular response, which was also better with asciminib. For example, the MR 4.5, which is a deep response, was 2.5% versus 0.4% favoring asciminib by week 12. So, I think in conclusion, these results build on the ASC4FIRST study, making the case for the superior safety and efficacy of asciminib versus other first- or second-generation TKIs in newly diagnosed CML. Dr. John Sweetenham: Thanks, Marc. Do you think this is going to change practice? Dr. Marc Braunstein: I think so. I think there are still some questions to be answered, such as what resistance mutations occur after first-line treatment with asciminib. But I think the sum of these studies really make the case for using asciminib upfront in CML. Dr. John Sweetenham: Okay, great. Thank you. And let's move on to our second abstract. This was Abstract 7015 and was reported from Mass General Hospital. And this was a study in patients with relapsed and refractory diffuse large B-cell lymphoma and reported the 2-year results of the so-called STARGLO study. This is a comparison of glofitamab, a T-cell engaging bispecific antibody, with gemcitabine and oxaliplatin in this group of patients. Can you tell us a little bit about your impressions of this study? Dr. Marc Braunstein: Absolutely. So just for background, the treatment landscape for relapsed/refractory large B-cell lymphoma is expanding, now with two bispecific antibodies targeting CD20 that are approved after two or more lines of therapy. Among these, glofitamab was approved in 2023 based on phase 2 data showing an objective response rate of 52%, with 39% complete responses in relapsed/refractory large B-cell lymphoma patients after a median of three prior lines of therapy. Distinguishing glofitamab from epcoritamab, the other approved bispecific, glofitamab was given for 12 cycles and then stopped. Additionally, when combined with gemcitabine and oxaliplatin in the phase 3 STARGLO study, there was significantly improved overall survival compared to rituximab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory large B-cell lymphoma patients at a median follow-up of 11 months.  The authors of that study published last year in Lancet now present at ASCO this year the 2-year follow-up of the STARGLO study. Two hundred and seventy-four patients with a median of one prior line of therapy were randomized two-to-one to glofitamab plus GemOx versus rituximab plus GemOx, with the primary endpoint of overall survival. Here, the median overall survival was not reached versus 13.5 months, with a median PFS also significantly improved at about 14 months versus 4 months in the control. CRS of note in the glofitamab arm was mostly grade 1 or 2, with only about 2.3% grade 3 events. And three of the four patients had grade 1 or 2 neurotoxicity. So, John, putting this into context, I think it's encouraging that we now have randomized data showing the superiority of a bispecific plus chemotherapy over rituximab plus chemotherapy in transplant-ineligible patients. And while only 8% of the patients in the STARGLO study had prior anti-CD19 CAR T-cell therapy, I think this regimen could be considered in those patients who are ineligible for transplant or CAR T-cell therapy. Dr. John Sweetenham: Yeah, I agree. I think a couple of other compelling numbers to me were the fact that around 55% of these patients were alive at 2 years in the group who'd received glofitamab, and that almost 90% of those having that arm of the study who had a CR at the end of treatment were alive at 12 months. So, clearly, it's an active agent and also a kind of great off-the-shelf fixed-duration alternative in these relapsed and refractory patients. Dr. Marc Braunstein: I agree, and I would also note that the phase 3 SKYGLO study is looking at glofitamab plus Pola-R-CHP versus Pola-R-CHP alone. So, we may even be using these eventually in the first-line setting. Dr. John Sweetenham: Absolutely. Let's stay on the theme of diffuse large B-cell lymphoma and look at one other abstract in that space, which was Abstract 7000. This was a study from the HOVON group in the Netherlands, which looked at the prospective validation of end-of-treatment circulating tumor DNA in the context of a national randomized trial. What are your thoughts on this? Dr. Marc Braunstein: So, non-invasive liquid biopsies to detect and monitor cancers via circulating tumor-derived DNA or ctDNA, you know, is really emerging as a valuable tool in both solid and liquid tumors to understand disease biology, and also for drug development. So, to date, the most established application of ctDNA in lymphoma, I would say, is really for monitoring of minimal residual disease. So, in this correlative study by Steven Wang and colleagues in the HOVON group, they evaluated the prognostic significance of MRD status as assessed by ctDNA following first-line treatment with curative intent with either R-CHOP or dose-adjusted R-EPOCH. At the end of treatment, encouragingly, 76% of patients were MRD-negative, and 24% were MRD-positive. Now, of note, MRD-positive status at the end of treatment predicted inferior progression-free survival at 2 years, with only 28% of patients who are MRD-positive being progression-free versus 88% who are MRD-negative. And in fact, all the patients who failed to achieve a complete response after first-line treatment and were MRD-positive ultimately relapsed. So, circulating tumor cells are rarely found in large B-cell lymphomas, and so this study really builds on accumulating data that ctDNA has clinical value to detect residual disease with a non-invasive approach. So, there are many implications of how we could potentially use this to detect early signs of relapse, to potentially escalate treatment for consolidation if patients remain MRD-positive. So, I think this will eventually become utilized in clinical practice. Dr. John Sweetenham: Yeah, I agree. I think it's interesting that it provided an independent assessment of response, which was independent, in fact, of the results of PET-CT scanning and so on, which I think was very interesting to me. And the authors of the abstract actually commented in their presentation that they think this should be integrated as part of the standard response assessment now for patients with large B-cell lymphoma. Would you agree with that? Dr. Marc Braunstein: I would. For one thing, it allows repeated sampling. It's a non-invasive approach; it doesn't necessarily require a bone marrow biopsy, and it may have more sensitivity than conventional response measures. So, I think having a standardized system to assess ctDNA will be helpful, and definitely, I think this will be a valuable biomarker of disease response. Dr. John Sweetenham: Okay, great. Thanks. We're going to change gear again now, and we're going to highlight two abstracts in the multiple myeloma space. The first one of these is Abstract 7507. And this abstract reported on the long-term results of the CARTITUDE study for patients with relapsed and refractory multiple myeloma. What are your comments on this presentation? Dr. Marc Braunstein: So, this study actually got a lot of press, and I've already had multiple patients asking me about CAR T-cells as a result. Just as some background, CAR T-cells targeting BCMA, which is pretty much universally expressed on malignant plasma cells in myeloma, have really shown remarkable responses, especially in heavily pretreated patients, showing superior progression-free survival in both later and earlier phases of the disease, including in randomized studies in patients with second-line or beyond. So, the CARTITUDE-1 was really the original Phase 1/2 study of ciltacabtagene autoleucel, one of the two approved anti-BCMA CAR T-cell products, which was investigated in patients with a median of six to seven prior lines of therapy. So, these were patients who were pretty heavily pretreated. So, in the study presented by Voorhees at this year's ASCO meeting, this was the long-term follow-up at a median of 5 years from the one-time CAR infusion in these patients with a median of five prior lines of therapy. And remarkably, of the 97 patients, 33% remained progression-free at 5 years plus, without needing any further myeloma treatment during that time. And among those 33% of patients, 23% had high-risk cytogenetics, which we know are notoriously difficult to achieve responses in. What was interesting that they presented as correlative studies was there were some biomarkers that were distinguishing the patients who had the long PFS, including enrichment of more naive T-cells in the product, lower neutrophil-to-T-cell ratio, higher hemoglobin and platelets at baseline, and higher CAR T-cell levels relative to soluble BCMA levels. And the fact that they reported a median overall survival of 61 months in these really heavily pretreated patients, I think these data are impressive. I think we're going to continue to be using CAR T even earlier in the disease status than fifth or sixth line, as it was studied in CARTITUDE-1. There are even ongoing studies looking at first-line treatment with CAR T-cells. Dr. John Sweetenham: So, do you think that those 33% of patients who are disease-free at 5 years, do you think any of those are cured?  Dr. Marc Braunstein: That was one of the headlines in the press. I think if we're going to discuss things like "operational cures," where we're transforming myeloma into really a chronic disease, where patients can live practically a normal life expectancy, I think the measure of 5 years, especially in this population that was explored in CARTITUDE-1, I think we can call that close to a cure. Dr. John Sweetenham: Okay. Well, thank you. Exciting data, for sure. We're going to conclude today with another abstract in the multiple myeloma space. And this was Abstract 7500, which looked at an MRD, minimal residual disease-driven strategy following induction and transplant-eligible newly diagnosed multiple myeloma patients and reported on the primary endpoints of the phase 3 MIDAS trial. Can you walk us through this one, Marc? Dr. Marc Braunstein: Absolutely. It is a bit more complicated than the prior one we discussed because this is a randomized study with four arms. So, I'll start by saying that anti-CD38-based quadruplet regimens continue to show superior outcomes in both transplant-eligible and -ineligible newly diagnosed multiple myeloma patients. The MIDAS study mentioned is an open-label phase 3 trial with four arms in transplant-eligible newly diagnosed myeloma patients.  And initially, these patients were all treated with quadruplet therapy with the anti-CD38 antibody isatuximab combined with carfilzomib, lenalidomide, and dexamethasone in 718 newly diagnosed myeloma patients. So, they received the quadruplet regimen for six cycles and then were randomized based on their MRD status at 10 to the negative fifth following six cycles of induction. And that first randomization, if they were MRD-negative, was to either consolidation with six more cycles of the quadruplet regimen or transplant, autologous transplant, plus two cycles additionally of the quadruplet regimen. And both arms were followed by lenalidomide maintenance. The primary endpoint was MRD negativity at 10 to the negative sixth prior to entering the lenalidomide maintenance component. And in addition, the patients who were MRD-positive after induction were randomized to transplant plus two cycles of consolidation or a tandem autologous transplant. So, the median follow-up of the study was about 16 months, and the pre-maintenance rate of MRD negativity was high, between 84 to 86% between the two arms who were MRD-negative, which was not significantly different. And as far as the 233 patients who were MRD-positive, the pre-maintenance MRD negativity was also not significantly different at 40% for those who received autologous transplant, and 32% who received a tandem transplant. So, there's a lot of debate in the myeloma field about the evolving role of autologous transplant and whether transplant still plays a significant role in patients who are either MRD-negative after induction or who have deep remissions and are of standard risk. So, I think these data suggest that patients who are MRD-negative after induction with a quadruplet regimen studied here, which was Isa-KRd, plus consolidation, may possibly be able to forego consolidation with autologous transplant. And likewise, for those patients who are MRD-positive after induction, tandem transplant didn't seem to provide much of a benefit compared to single transplant, which is consistent with prior studies such as the StaMINA study. Dr. John Sweetenham: So, where do you think this leaves us, Marc? Are we going to need more studies before we have any definitive guidance on whether an autologous transplant is still appropriate for those patients who are MRD-negative? Dr. Marc Braunstein: Well, as clinicians, we want to do what's best for our patient. And in myeloma, the best we can do is to get as deep remissions as possible, meaning MRD negativity. And so, I think it's clear from the MIDAS study and others that quadruplet regimens provide the deepest remissions when given upfront. We can debate the role of autologous transplant. I think certainly the role of tandem autologous transplant is fading. But as far as a single autologous transplant as consolidation, I think it's reasonable as a goal to try to achieve MRD negativity after the transplant, especially for patients who remain MRD-positive after induction. Dr. John Sweetenham: Okay, great. Marc, thanks as always for sharing your insights on the heme malignancies studies from the ASCO meeting this year and for joining us on the ASCO Daily News Podcast. Always appreciate hearing your thoughtful and balanced input on these. Dr. Marc Braunstein: My pleasure. Thank you, John. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's guest:  Dr. John Sweetenham Dr. Marc Braunstein   @docbraunstein     Follow ASCO on social media:   @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:  Dr. John Sweetenham:  Consulting or Advisory Role: EMA Wellness  Dr. Marc Braunstein:  Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp  Speakers' Bureau: Janssen Oncology  Research Funding (Institution): Janssen, Celgene/BMS

Die Themen im heutigen Versicherungsfunk Update sind: BVK warnt vor Überregulierung in der Versicherungsvermittlung Der Bundesverband Deutscher Versicherungskaufleute (BVK) schlägt Alarm: Die Bürokratielast durch regulatorische Vorgaben überfordert nicht nur Versicherungsvermittler, sondern zunehmend auch Verbraucher. Anlass ist eine aktuelle Mystery-Shopping-Aktion der BaFin, die gravierende Auswirkungen überbordender Informationspflichten auf die Beratungsqualität zeigt. BVK-Präsident Michael H. Heinz fordert einen klaren Kurswechsel hin zu mehr Verständlichkeit und weniger Formalismus – im Sinne von Verbraucherschutz und Vermittlungspraxis. Unwetterschäden an Kfz: Versicherer zahlen 1,3 Mrd. EUR Sturm, Hagel und Überschwemmungen haben 2024 in Deutschland rund 340.000 kaskoversicherte Fahrzeuge beschädigt. Die Kfz-Versicherer zahlten 1,3 Mrd. EUR, so der GDV. Besonders betroffen waren Bayern, Baden-Württemberg und Thüringen – dort lag der durchschnittliche Schaden bei über 4.000 EUR. Die Versicherer warnen: Klimawandel verschärft das Unwetterrisiko. Cyberstudie: Heilwesen-Berufe besonders gefährdet Laut HDI Cyberstudie 2024 stuften 36 % der befragten Heilberufler ihr Risiko für eine Cyberattacke als hoch ein. 38 % waren bereits betroffen – meist durch Schadsoftware in E-Mails. Patientendaten gelten als besonders sensibel. Schwächen gibt es bei Multi-Faktor-Authentifizierung und simulierten Phishing-Angriffen. ASCORE bewertet 300 bKV-Tarife im neuen Produkt-Scoring 2025 ASCORE Analyse hat den neuen Scoring-Jahrgang 2025 für die betriebliche Krankenversicherung (bKV) veröffentlicht. Bewertet wurden 300 Tarife von 19 Gesellschaften. Neben einer Aktualisierung der Benchmarks flossen neue Kriterien und Differenzierungen ein – etwa zur Mitversicherung von Vorerkrankungen oder zur Erstattung gesetzlicher Zuzahlungen. Das zeigt: Der bKV-Bereich bleibt dynamisch und steht bei Krankenversicherern weiter im Fokus. SBK holt Platz 1 bei Krankenkassen-Befragung Die SBK Siemens-Betriebskrankenkasse ist laut aktueller Kundenbefragung des Deutschen Instituts für Service-Qualität (DISQ) die beliebteste gesetzliche Krankenkasse 2025. Die Studie unter gut 2.400 Versicherten zeigt: Mehr als die Hälfte der Anbieter erzielt nur ein „befriedigend“, vor allem bei Leistungsangebot und Transparenz. Trotz insgesamt solider Zufriedenheit denkt ein Drittel über einen Kassenwechsel nach. Platz 2 belegt die Audi BKK, gefolgt von der Techniker Krankenkasse. DIA-Studie 50plus: Jüngere erleben häufiger Altersdiskriminierung Laut Vorabergebnissen der neuen DIA-Studie 50plus berichten 25 % der 18- bis 29-Jährigen von Altersdiskriminierung – deutlich mehr als in älteren Altersgruppen. Ab 60 Jahren geben nur noch 11 % an, Benachteiligung wegen ihres Alters erlebt zu haben. Auch Diskriminierung im Umfeld wird von Jüngeren deutlich häufiger beobachtet. Die vollständige Studie wird in den kommenden Monaten veröffentlicht.

Florian Keisinger, seit wenigen Wochen neuer Hauptgeschäftsführer beim Zentralverband der deutschen Seehafenbetriebe (ZDS), tritt nur kurz nach seinem Amtsantritt mit einer ambitionierten Forderung an die Politik. Auf den ersten Blick klingt es gar nicht so viel: 3 %. Diesen Anteil vom Infrastruktur-Sondervermögen des Bundes fordert Keisinger für Investitionen in die Häfen als "kritische Infrastruktur". Ist das etwas tiefgestapelt? Übersetzt man das in eine absolute Zahl, wird die Dimension – auch im Vergleich zu bisherigen politischen Anstrengungen in diesem Feld – schon deutlicher: Es geht um mindestens 15 Mrd. €, sagt der neue ZDS-Chef und erläutert ausführlich die Hinter- und Beweggründe für die Initiative. Hinzu komme eine zweite große Herausforderung: die Grundlagen zu schaffen, "damit wir nicht wieder in die Situation kommen, in der wir jetzt sind. Dazu bedarf es einer entsprechenden Grundfinanzierung für die deutschen Seehäfen, die deutlich über der Summe liegt, die derzeit vom Bund zur Verfügung gestellt wird", so Keisinger, der seine Ansicht zu einer "angemessenen Hausnummer" erläutert. Infrastruktur-Sondervermögen, Energiewende, Bundeswehr – all das sind für ihn Themen, die auch die Seehäfen »sehr sehr konkret« betreffen. Keisinger ist im Mai aus der Luftfahrtbranche von Airbus Defence and Space zum ZDS gestoßen und bringt dadurch einige Erfahrungen aus dem Sicherheitsbereich mit. Im Podcast spricht er darüber, wie seine ersten Wochen in der "blauen" Wirtschaft verlaufen sind, was ihn überrascht hat, über seinen Quereinstieg und wie er von seinen bisherigen Erfahrungen im neuen Job zehren kann ("zahlreiche Anknüpfungspunkte"). Er spricht über eine massive Vernachlässigung und einen großen Sanierungsstau aus den letzten Jahrzehnten, neue Realitäten. Auch auf die Frage, wie seiner Ansicht nach der Einstieg ausländischer Unternehmen, etwa des chinesischen Staatskonzerns Cosco oder der MSC-Gruppe, in der aktuellen Situation zu bewerten ist, geht er ein. Die Stichworte lauten "Keine kategorische Abwehrreaktion" und »Abschottung«. Das Gespräch dreht sich außerdem um die Zeitenwende, den neuen maritimen Koordinator, Häfen als Basis für Offshore-Industrie und Energiewende, die Koordination zwischen dem Bund und den Ländern, Investitionen aus dem Verteidigungshaushalt, die vieldiskutierte Einfuhrumsatzsteuer, Automation in Häfen und Gespräche mit Gewerkschaften sowie die Wettbewerbsfähigkeit deutscher Seehäfen.

Drs. Brander and Cohen discuss the growing role of measurable residual disease (MRD) testing in CLL and its clinical implications.

Auf rund 41 Mrd. Euro belief sich Ende 2024 der Gegenwert der Goldreserven der Europäischen Zentralbank. Ein sehr viel kleineres Stück Gold nutzte EZB-Präsidentin Lagarde auf der Pressekonferenz nach der jüngsten Ratssitzung, um ein Statement hinsichtlich der Gerüchte um ein vorzeitiges Ende ihrer Amtszeit abzugeben. Aber auch um Zinsen und Geldpolitik ging es natürlich; im Gespräch mit Sebastian Franke ordnet Carsten Brzeski die beschlossene Leitzinssenkung um 25 Basispunkte ein.

In this JCO Article Insights episode, host Michael Hughes summarizes "Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma" by Kaiser et al, published February 18, 2025, followed by an interview with JCO Associate Editor Suzanne Lentzsch. Transcript Michael Hughes: Welcome to this episode of JCO Article Insights. This is Michael Hughes, JCO's editorial fellow. Today I have the privilege and pleasure of interviewing Dr. Suzanne Lentzsch on the “Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma” by Dr. Kaiser and colleagues. At the time of this recording, our guest has disclosures that will be linked in the transcript. The urge to identify patients with aggressive disease, which is the first step in any effort to provide personalized medical care, is intuitive to physicians today. Multiple myeloma patients have experienced heterogeneous outcomes since we first started characterizing the disease. Some patients live for decades after treatment. Some, irrespective of treatment administered, exhibit rapidly relapsing disease. We term this ‘high-risk myeloma'. The Durie-Salmon Risk Stratification System, introduced in 1975, was the first formal effort to identify those patients with aggressive, high-risk myeloma. However, the introduction of novel approaches in therapeutic agents—autologous stem cell transplantation with melphalan conditioning, proteasome inhibitors like bortezomib, or immunomodulatory drugs like lenalidomide—rendered the Durie-Salmon system a less precise predictor of outcomes. The International Staging System in 2005, predicated upon the burden of disease as measured by beta-2 microglobulin and serum albumin, was the second attempt at identifying high-risk myeloma. It was eventually supplanted by the Revised International Staging System (RISS) in 2015, which incorporated novel clinical and cytogenetic markers and remains the primary way physicians think about the risk of progression or relapse in multiple myeloma. Much attention has been focused on the canonically high-risk cytogenetic abnormalities in myeloma, typically identified by fluorescence in situ hybridization: translocation t(4;14), translocation t(14;16), translocation t(14;20), and deletion of 17p. Much attention also has been focused on the fact that intermediate-risk disease, as defined by the RISS, has been shown to be a heterogeneous subgroup in terms of survival outcomes. The RISS underwent revision in 2022 to account for such heterogeneity and has become the R2-ISS, published here in the Journal of Clinical Oncology first in 2022. Translocations t(14;16) and t(14;20) were removed, and gain or amplification of 1q was added. Such revisions to core parts of a modern risk-stratification system reflect the fact that myeloma right now is in flux, both in treatment paradigms and risk-stratification systems. The field in recent years has undergone numerous remarkable changes, from the advent of anti-CD38 agents to the introduction of cellular and bispecific therapies, to the very technology we use to investigate genetic lesions. The major issue is that we're seeing numerous trials using different criteria for the definition of high-risk multiple myeloma. This is a burgeoning problem and speaks very much now to a critical need for an effort to consolidate all these criteria on at least cytogenetic lesions as we move into an era of response-adapted treatment strategies. The excellent article by Kaiser and colleagues, published in the February 2024 edition of the JCO, does just that in a far-ranging meta-analysis of data from 24 prospective therapeutic trials. All 24 trials were phase II or III randomized controlled trials for newly diagnosed and relapsed/refractory multiple myeloma. The paper takes a federated analysis approach: participants provided summaries and performed prespecified uniform analyses. The high-risk cytogenetic abnormalities examined were translocation t(4;14), gain or amplification of 1q, deletion of 17p, and translocation t(14;16), if included in the original trials. All of these were collected into zero, single, or double-hit categories, not unlike the system currently present in diffuse large B-cell lymphomas. The outcomes studied were progression-free survival and overall survival, with these analyses adhering to modified ITT principles. The authors also performed prespecified subgroup analyses in the following: transplant-eligible newly diagnosed myeloma, transplant non-ineligible newly diagnosed myeloma, and relapsed/refractory myeloma. They, in addition, described heterogeneity by the I2 statistic, which, if above 50%, denotes substantial heterogeneity by the Cochrane Review Handbook, and otherwise performed sensitivity analyses and assessed bias to confirm the robustness of their results. In terms of those results, looking at the data collected, there was an appropriate spread of anti-CD38-containing and non-containing trials. 7,724 patients were evaluable of a total 13,926 enrolled in those 24 trials: 4,106 from nine trials in transplant-eligible myeloma, 1,816 from seven trials in transplant non-ineligible myeloma, and 1,802 from eight trials in relapsed/refractory disease. ISS stage for all patients was relatively evenly spread: stage I, 34.5%; stage II, 37%; stage III, 24%. In terms of high-risk cytogenetic lesions, double-hit disease was present in 13.8% of patients, and single-hit disease was present in 37.4%. In terms of outcomes, Kaiser and colleagues found a consistent separation in survival outcomes when the cohort was stratified by the number of high-risk cytogenetic lesions present. For PFS, the hazard ratio was for double-hit 2.28, for single-hit 1.51, without significant heterogeneity. For overall survival, the hazard ratio was for double-hit disease 2.94, single-hit disease 1.69, without significant heterogeneity except in patients with double-hit disease at 56.5%. By clinical subgroups, hazard ratios remained pretty consistent with the overall cohort analysis. In transplant-eligible newly diagnosed myeloma, the hazard ratio for progression is 2.53, overall survival 4.17. For transplant non-ineligible, 1.97 progression, 2.31 mortality. Relapsed/refractory disease progression 2.05, overall mortality 2.21, without significant heterogeneity. Of trials which started recruitment since 2015, that is to say, since daratumumab was FDA approved and thus since an anti-CD38 agent was incorporated into these regimens, analysis revealed the same results, with double-hit myeloma still experiencing worse survival by far of the three categories analyzed. Risk of bias overall was low by advanced statistical analysis. In terms of subgroup analysis, double-hit results for transplant-eligible newly diagnosed myeloma may have been skewed by smaller study effects, where the upper bound of the estimated hazard ratio for mortality reached into the 15 to 20 range. In conclusion, from a massive amount of data comes a very elegant way to think about the role certain cytogenetic abnormalities play in multiple myeloma. A simple number of lesions - zero, one, or at least two - can risk-stratify. This is a powerful new prognostic biomarker candidate and, somewhat soberingly, also may confirm, or at least suggests, that anti-CD38 agents are unable to overcome the deleterious impact of certain biologic characteristics of myeloma. Where do we go from here? This certainly needs further a priori prospective validation. This did not include cellular therapies. The very scale at which this risk-stratification system operates, agnostic to specific genetic lesion, let alone point mutations, lends itself also to further exploration. And to discuss this piece further, we welcome the one and only Dr. Suzanne Lentzsch to the episode. Dr. Lentzsch serves as an associate editor for JCO and is a world-renowned leader at the bleeding edge of plasma cell dyscrasia research. Dr. Lentzsch, there are several new investigations which suggest that translocation t(4;14), for example, is itself a heterogeneous collection of patients. There are other studies which suggest that point mutations in oncogenes like TP53, which were not assessed in Kaiser et al., carry substantial detrimental impact. Is this classification system - no-hit, single-hit, double-hit - too broad a look at tumor genetics? And how do you think we will end up incorporating ever more detailed investigations into the genetics of multiple myeloma moving forward? Dr. Suzanne Lentzsch: Michael, first of all, excellent presentation of that very important trial. Great summary. And of course, it's a pleasure to be here with JCO and with you to discuss that manuscript. Let me go back a little bit to high-risk multiple myeloma. I think over the last years, we had a lot of information on what is high-risk multiple myeloma, and I just want to mention a couple of things, that we separate not only cytogenetically high-risk multiple myeloma, we also have functional high-risk multiple myeloma, with an early relapse after transplant, within 12 months, or two years after start of treatment for the non transplant patients, which is difficult to assess because you cannot decide whether this is a high-risk patient before you start treatment. You only know that in retrospective. Other forms of high-risk: extramedullary disease, circulating tumor cells/plasma cell dyscrasia, patients who never achieve MRD positivity, extramedullary multiple myeloma, or even age and frailty is a high risk for our patients. Then we have gene expression and gene sequencing. So there is so much information currently to really assess what is high-risk multiple myeloma, that is very difficult to find common ground and establish something for future clinical trials. So what Dr. Kaiser did was really to develop a very elegant system with information we should all have. He used four factors: translocation t(14;16), t(4;14), gain or amplification of 1q, and deletion of 17p. Of course, this is not the entire, I would say, information we have on high risk, but I think it's a good standard. It's a very elegant system to really classify a standard single-hit, double-hit, high-risk multiple myeloma, which can be used for all physicians who treat multiple myeloma, and especially, it might also work in resource-scarce settings. So, ultimately, I think that system is an easy-to-use baseline for our patients and provides the best information we can get, especially with a baseline, in order to compare clinical trials or to compare any data in the future. Michael Hughes: Thank you, Dr. Lentzsch. To the point that you made about this isn't the full story. There does, as you said, exist this persistent group of functional high-risk multiple myeloma where we see standard-risk cytogenetics, but these patients ultimately either exhibit primary refractory disease or very early relapse despite aggressive, standard aggressive treatment. How do you see risk-stratification systems incorporating other novel biomarkers for such patients? Is it truly all genetic? Or is next-generation sequencing, gene expression profiling, is that the answer? Or is there still a role for characterizing tumor burden? Dr. Suzanne Lentzsch: Excellent question, Michael, and I wish I would have the glass ball to answer that question. I see some problems with the current approach we have. First of all, to do the cytogenetics, you need good material. You only detect and identify what you have. If the bone marrow is of low quality, you have mainly peripheral blood in your bone marrow biopsy, you might not really fully have a representation of all cytogenetic changes in your bone marrow. So I think with a low-quality sample, that you might miss one or the other really cytogenetic high risk. So, having said this, I think circulating tumor cells, that might be something we will look into in the future, because circulating tumor cells are readily available, can be assessed without doing a bone marrow biopsy. And what is even more exciting, in addition to the circulating tumor cells or plasma cells, using them is next-generation sequencing. I think at the moment, we are more in a collection phase where we really try to correlate sequencing with our cytogenetics and especially to establish next-generation sequencing in all of our patients. But I think after that collection phase, maybe in the future, collecting peripheral blood and doing sequencing on peripheral blood samples might be the way to go. In addition, I don't want to forget the imaging. We started with a skeletal survey, and we know that you probably need to lose 30% of the bone before you see a lesion at all. So having imaging, such as diffusion-weighted imaging, whole-body MRI, is also, together with sequencing of the tumor cells, a step into the right direction. Michael Hughes: Thank you, Dr. Lentzsch. Bringing this back to the article at hand, how has Kaiser et al. changed the way we discuss myeloma with patients in the exam room? Dr. Suzanne Lentzsch: I think we have more data on hand. So far, we talked about standard risk and high risk, but I think right now, with a very simple system, we can go into the room and we can tell the patient, "Listen, you don't have any of those cytogenetic abnormalities. I think you have a standard risk. We might give you a simple maintenance treatment with Revlimid." But we might also go into the room and say, "I'm really concerned. You have so-called double-hit multiple myeloma. You have high-risk and at least two of those abnormal cytogenetics which we discussed, and I think you need a more intense maintenance treatment, for instance, double maintenance." I think we know that a high-risk multiple myeloma can be brought into a remission, but the problem that we have is to keep those patients into a remission. So, I think a more intense treatment, for instance, with a double maintenance, or with consolidation after transplant, and a longer and more intense treatment is justified in patients who have that truly high-risk multiple myeloma described here. Michael Hughes: Dr. Lentzsch, thank you so much for your time and your wisdom. Dr. Suzanne Lentzsch: My pleasure. Thank you for having me. Michael Hughes: Listeners, thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit ASCO.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Oracle kauft einmal den Quartalsumsatz von Nvidia für ein OpenAI Datacenter. Tim Cooks Einfluss auf Präsident Trump steht auf dem Prüfstand. Meta verliert KI-Talente an das Pariser Startup Mistral. Verstößt Shein mit seinen Verkaufstaktiken gegen EU-Recht und drohen dem Fast-Fashion-Riesen aus China nun hohe Strafen? SoftBanks Masayoshi Son plant einen Fonds zwischen den USA und Japan. Die Trump Media Group will 3 Milliarden Dollar in Kryptowährungen investieren. Immer mehr Menschen suchen bei ChatGPT nach schonungslosen Schönheitstipps. ChatGPT o3 hat angeblich eine Abschaltung umgangen und damit Fragen zur Kontrolle von KI-Systemen aufgeworfen. Unterstütze unseren Podcast und entdecke die Angebote unserer Werbepartner auf ⁠⁠⁠⁠⁠doppelgaenger.io/werbung⁠⁠⁠⁠⁠. Vielen Dank!  Philipp Glöckler und Philipp Klöckner sprechen heute über: (00:00:00) Trump Apple Zölle (00:09:50) Oracle OpenAI (00:15:45) Meta Llama Talentverlust  (00:22:00) Shein EU Verbraucherschutz  (00:26:50) Masayoshi Son US Japan Staatsfonds (00:31:40) Trump Memecoin Gala  (00:34:00 ) Kryptoinvestor Entführung  (00:41:50) ChatGPT Schönheitstipps & Shutdown Umgehung  Shownotes Techs Trump-Flüsterer Tim Cook wird leiser – nytimes.com Oracle $40bn für OpenAI's data centre – ft.com Elon Musk Twitter – x.com Stargate Video – Bloomberg Metas Llama-AI-Team verliert Talente an Mistral. – businessinsider Wird MAGA Mark Zuckerberg zurück lieben? – Bloomberg Shein verstößt gegen EU-Verbraucherschutzregeln – wsj.com SoftBank: Masayoshi Son schlägt US-Japan Staatsfonds vor – ft.com Trumps Memecoin-Galadinner zieht Krypto-Tycoons, Basketballstar und Proteste an – wsj.com Krypto-Investor wegen Entführung und Folterung angeklagt – nytimes.com Trump-Mediengruppe plant, $3 Mrd. in Kryptowährungen zu investieren – ft.com Menschen fragen ChatGPT nach ehrlichem Schönheitsrat – washingtonpost.com AI Image Gen Bias – washingstonpost.com Latina Bias – bloomberg Forscher behaupten, ChatGPT o3 umging Abschaltung im Test – bleepingcomputer.com

Die Reaktion auf die meisten seit gestern Abend gemeldeten Ergebnisse ist positiv, mit den Aktien Advance Auto Parts, Analog Devices, Snowflake und Urban Outfitters besonders fest. Zoom tendiert nach den Zahlen kaum verändert. Wie von vielen an der Wall Street hat das Repräsentantenhaus die Reconciliation Bill genehmigt. Damit nimmt die geplante Steuer- und Ausgabenreformen die erste wichtige Hürde. Im zweiten Schritt muss nun der Senat den eigenen Gesetzesentwurf verabschieden, um dann im dritten Schritt eine gemeinsame Einigung zwischen beiden Häusern zu erreichen. Das Repräsentantenhaus sieht Kürzungen der Medicare-Ausgaben von $500 Mrd. vor. Das Krankenversicherungsprogramm für Personen über 65 Jahren, wie auch für Behinderte. Schätzungsweise 8 bis 13 Millionen Amerikaner laufen Gefahr ihre Krankenversicherung zu verlieren, was weitreichende Folgen haben wird. Trotz der Kürzungen sollen die Reformen die Defizite auf Sicht der nächsten 10 Jahre um rund $3 Billionen anfachen. Dementsprechend ziehen die Renditen der langlaufenden US-Staatsanleihen heute weiter an, was in Folge den Aktienmarkt belastet. Die Renditen 30-jähriger Staatsanleihen erreichen das höchste Niveau seit 2007. Abonniere den Podcast, um keine Folge zu verpassen! ____ Folge uns, um auf dem Laufenden zu bleiben: • X: http://fal.cn/SQtwitter • LinkedIn: http://fal.cn/SQlinkedin • Instagram: http://fal.cn/SQInstagram

Die Reaktion auf die meisten seit gestern Abend gemeldeten Ergebnisse ist positiv, mit den Aktien Advance Auto Parts, Analog Devices, Snowflake und Urban Outfitters besonders fest. Zoom tendiert nach den Zahlen kaum verändert. Wie von vielen an der Wall Street hat das Repräsentantenhaus die Reconciliation Bill genehmigt. Damit nimmt die geplante Steuer- und Ausgabenreformen die erste wichtige Hürde. Im zweiten Schritt muss nun der Senat den eigenen Gesetzesentwurf verabschieden, um dann im dritten Schritt eine gemeinsame Einigung zwischen beiden Häusern zu erreichen. Das Repräsentantenhaus sieht Kürzungen der Medicare-Ausgaben von $500 Mrd. vor. Das Krankenversicherungsprogramm für Personen über 65 Jahren, wie auch für Behinderte. Schätzungsweise 8 bis 13 Millionen Amerikaner laufen Gefahr ihre Krankenversicherung zu verlieren, was weitreichende Folgen haben wird. Trotz der Kürzungen sollen die Reformen die Defizite auf Sicht der nächsten 10 Jahre um rund $3 Billionen anfachen. Dementsprechend ziehen die Renditen der langlaufenden US-Staatsanleihen heute weiter an, was in Folge den Aktienmarkt belastet. Die Renditen 30-jähriger Staatsanleihen erreichen das höchste Niveau seit 2007. Ein Podcast - featured by Handelsblatt. +++Erhalte einen exklusiven 15% Rabatt auf Saily eSIM Datentarife! Lade die Saily-App herunter und benutze den Code wallstreet beim Bezahlen: https://saily.com/wallstreet +++ +++EXKLUSIVER NordVPN Deal ➼ https://nordvpn.com/Wallstreet Jetzt risikofrei testen mit einer 30-Tage-Geld-zurück-Garantie!+++ +++ Alle Rabattcodes und Infos zu unseren Werbepartnern findet ihr hier: https://linktr.ee/wallstreet_podcast +++ Der Podcast wird vermarktet durch die Ad Alliance. Die allgemeinen Datenschutzrichtlinien der Ad Alliance finden Sie unter https://datenschutz.ad-alliance.de/podcast.html Die Ad Alliance verarbeitet im Zusammenhang mit dem Angebot die Podcasts-Daten. Wenn Sie der automatischen Übermittlung der Daten widersprechen wollen, klicken Sie hier: https://datenschutz.ad-alliance.de/podcast.html

BUFFALO, NY – May 19, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 9, 2025, titled “Analytical validation of a circulating tumor DNA assay using PhasED-Seq technology for detecting residual disease in B-cell malignancies.” In this study, a team from Foresight Diagnostics led by first author Nina Klimova and corresponding author Laura Hyland validated a new DNA-based blood test designed to detect minimal residual disease (MRD) in patients with B-cell cancers. This assay uses a highly sensitive method called Phased Variant Enrichment and Detection Sequencing (PhasED-Seq) to find tiny fragments of tumor DNA in the blood. Its ultra-sensitive detection capabilities offer a powerful tool for early cancer detection, monitoring treatment response, and predicting cancer reappearance. B-cell lymphomas, such as diffuse large B-cell lymphoma (DLBCL), are among the most prevalent blood cancers. Although many patients respond to initial treatment, up to 40% relapse. Standard monitoring methods such as imaging scans often miss low levels of cancer cells, creating a need for more precise tools. This study introduces a non-invasive blood test that improves the detection of MRD, a critical factor in guiding follow-up care and early intervention. The test works by tracking unique groups of mutations known as phased variants in tumor DNA. These mutations are more specific to cancer and allow for highly accurate identification of tumor fragments in the bloodstream. The PhasED-Seq-based MRD assay was tested on three types of samples. First, blood plasma from healthy individuals was used to confirm the test does not give false positives. Second, researchers created controlled samples by mixing tumor DNA from lymphoma patients with healthy DNA to measure how sensitive and precise the test is. Finally, blood samples from patients with B-cell lymphoma were used to compare the new test to an existing method. Across all sample types, the PhasED-Seq-based MRD assay demonstrated exceptional performance—capable of detecting fewer than one cancer DNA molecule per million normal DNA fragments. It also demonstrated a very low false positive rate and over 96% reproducibility across different laboratory conditions. Compared to an existing method, the new PhasED-Seq assay showed more than 90% agreement in positive results and nearly 78% agreement in negative results. In cases where the tests disagreed, the new method aligned more closely with actual clinical outcomes, including whether patients relapsed or stayed in remission. “The background error rate of the PhasED-Seq-based MRD assay was 1.95E-08, or 1.95 mutant molecules in 100 million informative molecules.” The findings support the use of PhasED-Seq-based MRD assays in routine clinical practice. It could be especially useful for identifying patients who need additional treatment even when imaging results appear normal. This aligns with updated clinical guidelines that encourage the use of blood-based DNA tests to supplement traditional scans in lymphoma care. This study offers strong evidence that the PhasED-Seq-based MRD assay is a precise, reliable, and clinically relevant tool. By detecting signs of cancer earlier and more accurately, it may help clinicians tailor treatments to individual patients and improve long-term outcomes in B-cell malignancies. DOI - https://doi.org/10.18632/oncotarget.28719 Correspondence to - Laura Hyland - laura.hyland@foresight-dx.com Video short - https://www.youtube.com/watch?v=8hdh3G5zvlc Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In this week's episode, we'll learn about stopping myeloma maintenance therapy in the modern era. New research suggests that many patients in remission can discontinue lenalidomide, remaining treatment-free, without jeopardizing disease response. After that: a novel congenital neutropenia syndrome. Mutations in the COPZ1 gene impact myeloid differentiation and development of neutropenia. Researchers describe the mechanisms and propose a treatment strategy for restoring granulopoiesis. Finally, ruxolitinib maintenance therapy after allogeneic transplant. In a phase 2 study, this treatment strategy was associated with low rates of chronic graft-versus-host disease. Investigators say the use of JAK inhibitors in this context warrants further study.Featured Articles: Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myelomaA new severe congenital neutropenia syndrome associated with autosomal recessive COPZ1 mutationsLow rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

Buffett tritt ab – und übergibt Greg Abel die Verantwortung für rund 600 Milliarden Dollar verfügbares Kapital in den kommenden fünf Jahren! Was bedeutet das für Berkshire Hathaway? In dieser Folge tauscht sich Tobias mit Alex Fischer von dividenden-alarm.de aus: • Was vom Buffett-Wochenende bleibt: Rückblick auf die Hauptversammlung in Omaha • Greg Abels Challenge: 100 Mrd. $ pro Jahr investieren – aber wie? • Drei Sektoren mit Potenzial: • Energie – Sonne und Wind mit Milliarden-Investment-Potenzial • Handel & Industrie Japan – mit Fokus auf Itoshu, Marubeni & Co. • Tabak – von Altria bis Philip Morris: Dividenden, Burggraben, Bewertung • Vier konkrete Investment-Cases: • Alphabet (WKN: A14Y6F): Günstiger Einstieg in Tech-Beteiligung mit Burggraben möglich. Nach Apple's AI-Einlassungen noch günstiger - timing is a … • Disney (WKN: 855686): Re-Entry nach Zahlen, Brandpower, Streaming & Parks • Kenvue (WKN: A3EEHU): Johnson&Johnson-Spin-off mit Alltagsrendite • UPS (WKN: 929198): Dividendenriese im zyklischen Tief – Buffett-Style • Buffetts Kriterien im Fokus: Einfaches Geschäftsmodell, Wettbewerbsvorteil, solides Management, niedrige Bewertung ▶️ Jetzt reinschauen und mitdiskutieren: Welche Aktien würdet ihr Greg Abel empfehlen – und warum? ➡️ Kinderdepots bei Scalable – jetzt auf die Warteliste setzen! https://de.scalable.capital/kinderdepot

Wir lassen den ersten Tag der OMR revue passieren. Was ist eine Public Benefit Company, wieso wird OpenAI doch kein For-Profit? Apples partnert mit Anthropic. Die App Cursor erreicht eine Bewertung von 9 Milliarden Dollar. Spotifys neue "Plays"-Funktion verändert vielleicht die Podcast-Landschaft. Trumps Krypto-Imperium steht im Verdacht, der größte Korruptionsskandal der US-Geschichte zu werden, nachdem eine Firma aus Abu Dhabi 2 Milliarden Dollar investiert hat. Unterstütze unseren Podcast und entdecke die Angebote unserer Werbepartner auf ⁠⁠⁠doppelgaenger.io/werbung⁠⁠⁠. Vielen Dank! Philipp Glöckler und Philipp Klöckner sprechen heute über: (00:00:00) OMR Tag 1 Recap (00:19:10) Politik heute kippen (00:19:30) OpenAI Nonprofit (00:23:10) Apple Xcode Claude (00:27:30) Temu & Shein (00:30:30) Spotify Podcast Plays (00:34:15) Northern Data Update (00:37:45) Palantir Earnings (00:40:45)Hims Earnings (00:42:00) Starbase (00:43:15) Trump Krypto Korruption Abu Dhabi Shownotes OpenAI For Profit Transformation gestoppt – axios.com Apple integriert Anthropic in XCode – bloomberg.com Hersteller der KI-App Cursor erreicht $9 Mrd. Bewertung – ft.com US Regierung Signal Hack – 404media.co Shein, Temu verstärken Werbung in UK und Frankreich – reuters.com Spotify zeigt Aufrufzahlen von Podcast-Episoden – techcrunch.com Northern Data Group Ad Hoc News – ad-hoc-news.de Starbase – apnews.com Trump Krypto-Korruption verschärft sich durch $2 Milliarden Investition von Abu Dhabi – rollingstone.com

A masterclass from the legend Zahid Hussain. A must-watch for anyone interested in learning the fundamental problems with Pakistan's political structure and the historical fault lines.On this podcast, we discuss Zia-ul-Haq's era, Iskander Mirza and the early years, Bacha Khan, Jamat-e-Islami, MRD, Jam Saqi, Zulfiqar Ali Bhutto, Mohajir Nationalism, The creation of MQM, IJI, TTP, Balochistan and more. Zahid Hussain is a Pakistani journalist, writer and television analyst. Hussain is a correspondent covering Pakistan and Afghanistan for The Times of London and The Wall Street Journal. His work has included assignments for Newsweek, the Associated Press, The Economist and several other international publicationsThe Pakistan Experience is an independently produced podcast looking to tell stories about Pakistan through conversations. Please consider supporting us on Patreon:https://www.patreon.com/thepakistanexperienceTo support the channel:Jazzcash/Easypaisa - 0325 -2982912Patreon.com/thepakistanexperienceAnd Please stay in touch:https://twitter.com/ThePakistanExp1https://www.facebook.com/thepakistanexperiencehttps://instagram.com/thepakistanexpeperienceThe podcast is hosted by comedian and writer, Shehzad Ghias Shaikh. Shehzad is a Fulbright scholar with a Masters in Theatre from Brooklyn College. He is also one of the foremost Stand-up comedians in Pakistan and frequently writes for numerous publications. Instagram.com/shehzadghiasshaikhFacebook.com/Shehzadghias/Twitter.com/shehzad89Join this channel to get access to perks:https://www.youtube.com/channel/UC44l9XMwecN5nSgIF2Dvivg/joinChapters:0:00 Introduction and Imran Khan interview4:50 Zia ul Haq's era10:00 Pakistan is a multi nation state18:16 Iskander Mirza and the Early Years23:21 Bacha Khan and Quaid e Azam28:30 Professor Ghaffor Ahmad and Jamaat-e-Islami36:00 Does Jamiat do violence on campus39:30 MRD Movement43:00 Jam Saqi and Zulfiqar Ali Bhutto45:00 Mairaj Muhammad Khan and Faces of Resistance51:00 MRD, Benazir Bhutto and resistance to Zia ul Haq59:30 Hamida Khuhro and Sindhi Nationalists1:03:08 Mohajir Nationalism and MQM1:19:00 1988 Elections and IJI1:22:40 Nawaz Sharif's interview1:26:50 Establishment vs PPP1:32:40 How the Establishment took control of Pakistan1:40:00 When Zahid Hussain met General Bajwa1:42:20 General Pervez Musharraf and TTP1:45:09 Balochistan1:58:00 Audience Questions